Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Mon, Aug 26
Tue, Aug 27
Wed, Aug 28
Poster Schedule
Type here to filter the list
Monday, August 26, 2024
8:00 AM – 6:00 PM
CEST
(001) Advancements in Rheumatoid Arthritis Management: An Analysis of Clinical Features and Treatment Outcomes in a Brazilian Cohort
Favorite
8:00 AM – 6:00 PM
CEST
(002) Assessment of medication adherence and its factors influencing poor medication adherence among psoriasis patients: a cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(003) Assessment of medication adherence and the impact of clinical pharmacist interventions on medication adherence among systemic lupus erythematosus patients: a prospective cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(004) Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids or Glucocorticoids Taper in a Real-World Setting
Favorite
8:00 AM – 6:00 PM
CEST
(005) Cohort studies on 71 different adverse health outcomes among people with atopic eczema in UK primary care data
Favorite
8:00 AM – 6:00 PM
CEST
(006) Determination of patients’ quality of life (QOL) and its influencing risk factors associated with QOL in patients with autoimmune systemic vasculitis: a cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(007) Determining lines of therapy in real world patients with rheumatoid arthritis: analyses of a nationwide claims database in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(008) Disease Activity in Rheumatoid Arthritis Patients Initiating Anti-Obesity Medication in a Longitudinal US-Based Real-World Cohort
Favorite
8:00 AM – 6:00 PM
CEST
(009) Drug survival and safety of biosimilars compared with originator adalimumab for Psoriasis: a multinational cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(010) Drug Survival of Baricitinib in Treatment-Naïve Patients with Rheumatoid Arthritis (RA): a population-based study
Favorite
8:00 AM – 6:00 PM
CEST
(011) Enhanced Pharmacovigilance to Contextualize 13 years of Monitoring: The Gilenya Pregnancy Registry put in Perspective with the Fingolimod PRegnancy outcomes Intensive Monitoring (PRIM) Program
Favorite
8:00 AM – 6:00 PM
CEST
(012) Ensuring Safety: A Comprehensive Review of the Subcutaneous Administration of Biologics
Favorite
8:00 AM – 6:00 PM
CEST
(013) Epidemiology and Disease Burden of Generalized Pustular Psoriasis – A Retrospective Cohort Study in Finland
Favorite
8:00 AM – 6:00 PM
CEST
(014) Establish a Prediction Model for Treatment Response of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Favorite
8:00 AM – 6:00 PM
CEST
(015) Estimating Prevalence of Moderate-to-Severe Systemic Lupus Erythematosus. A Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(016) Hormone Therapy and Risk of Psoriasis in Reproductive and Postmenopausal Women: A Nationwide Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(017) Immune Checkpoint Inhibitors and Overlap Syndrome of Myocarditis and Myositis or Myasthenia Gravis: Analysis of WHO VigiBase Database.
Favorite
8:00 AM – 6:00 PM
CEST
(018) Impact of Immune Checkpoint Inhibitors on Psoriasis Incidence: Emulation of a Randomized Target Trial Using Real-world Data
Favorite
8:00 AM – 6:00 PM
CEST
(019) Initial and subsequent biological therapies for patients with psoriasis vulgaris during 2010-2021 in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(020) Initiation Trends of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Adults in the United States from 2001 to 2021
Favorite
8:00 AM – 6:00 PM
CEST
(021) Line of Therapy of Biologics and JAK Inhibitors in RA, PsA, and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics
Favorite
8:00 AM – 6:00 PM
CEST
(022) Market Uptake and Pattern of Use of Emerging Topical Rosacea Medications in Switzerland: a Descriptive Study using Swiss Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(023) Medication persistence in the treatment of rheumatoid arthritis in the Brazilian Public Health System
Favorite
8:00 AM – 6:00 PM
CEST
(024) Mortality in an Eosinophilic Granulomatosis with Polyangiitis (EGPA) Incident Cohort: A Retrospective Study in England
Favorite
8:00 AM – 6:00 PM
CEST
(025) Overall survival in immune checkpoint inhibitor-treated patients with rheumatoid arthritis and non-small cell lung cancer: a Medicare claims study
Favorite
8:00 AM – 6:00 PM
CEST
(026) Potential Drug Interaction in Janus Kinase Inhibitors Users Among Patients with Rheumatoid Arthritis or Psoriatic arthritis in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(027) Prescribing Patterns of Biological Therapies in Psoriasis Management: A Retrospective Cohort Study in Saudi Arabia
Favorite
8:00 AM – 6:00 PM
CEST
(028) Prescription Patterns After the Approval of Dupilumab, Abrocitinib, Baricitinib, and Upadacitinib in Adults with Atopic Dermatitis: A Real-World Evidence from a Multi-Institutional Database in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(029) Prevalence of dermatomyositis and polymyositis in adults and paediatric populations: a network cohort study part of DARWIN EU®
Favorite
8:00 AM – 6:00 PM
CEST
(030) Prevalence, characteristics, and prescription pain medication use in the rheumatoid arthritis population
Favorite
8:00 AM – 6:00 PM
CEST
(031) Real-World Patterns in Treatment Switching to Biosimilar Adalimumab in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(032) Real-World Utilization Patterns of Immune Checkpoint Inhibitors: based on the National Health Insurance Service Data in Korea (2017-2022)
Favorite
8:00 AM – 6:00 PM
CEST
(033) Risk of hypertension and type 2 diabetes in patients with systemic lupus erythematous: A retrospective cohort study in Yinzhou, China
Favorite
8:00 AM – 6:00 PM
CEST
(034) Risk of safety outcomes associated with the long-term use of oral corticosteroids: A nested case-control study of 1 million patients with atopic dermatitis
Favorite
8:00 AM – 6:00 PM
CEST
(035) Safety Events in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis Exposed to Tofacitinib (Xeljanz) or Biologics: Real-World Data from the CARRA Registry
Favorite
8:00 AM – 6:00 PM
CEST
(036) Serious Infection Risk Associated With Biologics and Systemic Nonbiologics in Patients With Psoriasis: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Favorite
8:00 AM – 6:00 PM
CEST
(037) Switching proportion assessment in rheumatoid arthritis patients exposed to disease modifying anti-rheumatic drugs: systematic review and meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(038) Treatment of rheumatoid arthritis in the Brazilian Public Health System: medication use profile
Favorite
8:00 AM – 6:00 PM
CEST
(039) Treatment Patterns in Moderate to Severe Psoriasis: A Hospital-based Retrospective Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(040) Trends in Management of Inflammatory Bowel Disease in Sweden and Norway, 1982-2016
Favorite
8:00 AM – 6:00 PM
CEST
(041) Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi
Favorite
8:00 AM – 6:00 PM
CEST
(042) Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Favorite
8:00 AM – 6:00 PM
CEST
(043) Utilization of newly approved targeted immunomodulating treatments for atopic dermatitis
Favorite
8:00 AM – 6:00 PM
CEST
(044) Utilizing Real-World Data to Create an External Control Arm for a Phase 3 Trial of Deucravacitinib for Treatment of Plaque Psoriasis
Favorite
8:00 AM – 6:00 PM
CEST
(045) Vitiligo Disease Severity and Real-World Treatment Patterns
Favorite
8:00 AM – 6:00 PM
CEST
(046) Adverse Effects of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Patients with Chronic Myeloid Leukemia
Favorite
8:00 AM – 6:00 PM
CEST
(047) Anaphylaxis Risk and Long-Term Central Venous Catheter Use: a Health Plan Claims Database Analysis Comparing Subcutaneous and Intravenous Pertuzumab / Trastuzumab Administration in the US
Favorite
8:00 AM – 6:00 PM
CEST
(048) Antiangiogenic Drugs and the Risk of Arterial Dissection or Aneurysm in Patients with Metastatic Colorectal Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(049) Assess the applicability of capmatinib and tepotinib to real-world patients in Taiwan with MET mutations
Favorite
8:00 AM – 6:00 PM
CEST
(050) Association Between Aromatase Inhibitors and Dry Eye Disease Among Women with Breast Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(051) Assessment of Risk-Benefit Balance of Immune Checkpoint Inhibitors in a Real-World Lung Cancer Population
Favorite
8:00 AM – 6:00 PM
CEST
(052) Clinical Responses to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Patient Characteristics and Predictors
Favorite
8:00 AM – 6:00 PM
CEST
(053) Comparative Analysis on incident risk of Anemia and Immune-Mediated Hepatitis in non-small cell lung cancer (NSCLC): Enhancing Cross-Data Source Comparability in PD-1/PD-L1 Therapy
Favorite
8:00 AM – 6:00 PM
CEST
(054) Computational Drug Repurposing for gallbladder cancer integrated with pharmacovigilance approach
Favorite
8:00 AM – 6:00 PM
CEST
(055) Development and portability of a text mining algorithm for capturing disease progression in electronic health records of with stage IV non-small cell lung cancer treated with immuno-chemotherapy
Favorite
8:00 AM – 6:00 PM
CEST
(056) Examination of treatment patterns amongst drug classes in metastatic non-small cell lung cancer patients across EU4, UK, and US
Favorite
8:00 AM – 6:00 PM
CEST
(058) First-line therapy discontinuation among Brazilian multiple myeloma patients: incidence and reasons
Favorite
8:00 AM – 6:00 PM
CEST
(059) Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer: a cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(060) Genomic profiling and the need for immunotherapy in gastric cancer
Favorite
8:00 AM – 6:00 PM
CEST
(061) Healthcare Utilization among Cancer Patients Treated with Immune Checkpoint Inhibitors in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(062) Identifying Adverse Drug Reactions Through Knowledge Graph Modeling
Favorite
8:00 AM – 6:00 PM
CEST
(063) Identifying the Period of Heightened Risk for Adrenal Insufficiency in Patients with Advanced Non-Small Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(064) Incidence and risk of secondary myelodysplastic syndrome and acute myeloid leukaemia in ovarian cancer patients treated with poly-ADP ribose polymerase inhibitors in England
Favorite
8:00 AM – 6:00 PM
CEST
(065) Incidence of any Infections and SARS-COV-2 infections in Patients Receiving Treatment for Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Real-World Evidence from a Large US National Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(066) Incidence of Infections in Clinical Trials of Treatments for Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(068) Investigating the Effect of Concurrent Use of Angiotensin-Converting Enzyme Inhibitors or Receptor Blockers on Radiotherapy-related Toxicities and Treatment Outcome in Patients with Cancer: A Systematic Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(069) Isatuximab Adverse Event Monitoring: A Safety Meta-Analysis of Randomized Controlled Trials and Refining Signals through Pharmacovigilance Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(070) NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
Favorite
8:00 AM – 6:00 PM
CEST
(071) Ocular adverse events associated with platins: A disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports
Favorite
8:00 AM – 6:00 PM
CEST
(072) Patterns of Underreporting of Enrollment Dates in Cancer Clinical Trials: A HemOnc Knowledgebase Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(073) Pharmacometaboomics suggest a causal link between an excipient in cyclosporine A capsules and incomplete mycophenolate mofetil prodrug activation in kidney transplant recipients
Favorite
8:00 AM – 6:00 PM
CEST
(074) Progression-Free Survival (PFS) as a Surrogate for Overall Survival (OS) in Advanced Non-Small Cell Lung Cancer (aNSCLC): Analysis of Patient-Level Pooled Randomized Clinical Trials (RCTs)
Favorite
8:00 AM – 6:00 PM
CEST
(075) Real-World Treatment of Patients with Chronic Lymphocytic Leukemia: Results from Analysis of US Health Insurance Claims Dataset
Favorite
8:00 AM – 6:00 PM
CEST
(076) Real-World utilization of 1L systemic therapy amongst Black and Non-Hispanic White patients with advanced or recurrent endometrial cancer
Favorite
8:00 AM – 6:00 PM
CEST
(077) Replication of overall response in mNSCLC patients treated with pembrolizumab and chemotherapy using RECIST 1.1 criteria applied to images from the real world
Favorite
8:00 AM – 6:00 PM
CEST
(078) Risk Evaluation of Vascular Adverse Events in Chronic Myeloid Leukemia Patients Following First-Line TKI Therapy Initiation
Favorite
8:00 AM – 6:00 PM
CEST
(079) Synthesized Learnings and Considerations from Global Historical Cohort Studies via Retrospective Chart Review in Oncology
Favorite
8:00 AM – 6:00 PM
CEST
(080) The treatment modalities and radiotherapy pattern in patients of primary lung cancer with distant metastasis in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(081) The use of opioid and non-opioid analgesics and illicit drugs among patients with cancer in the U.S.: prevalence and association with mortality
Favorite
8:00 AM – 6:00 PM
CEST
(082) Use of Systemic and Topical Glucocorticoids and Risk of Skin Cancers in a Prospective Cohort of French Women.
Favorite
8:00 AM – 6:00 PM
CEST
(083) Utility of Digitally-Enabled Tools in Community Education and Activation for LDCT screening for Lung Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(084) A Cohort Study to Evaluate the Real-World Utilization and Effectiveness of Bebtelovimab Compared to Nirmatrelvir/Ritonavir among Patients with Mild-to-Moderate COVID-19 Who Are at High Risk for Progressing to Severe Illness
Favorite
8:00 AM – 6:00 PM
CEST
(085) Alterations in Influenza Management - the Potential Influence of the COVID-19 Pandemic
Favorite
8:00 AM – 6:00 PM
CEST
(086) Assessing the Robustness of Comparative Effectiveness Studies: An Applied Example Evaluating the Effectiveness of Bebtelovimab In COVID-19
Favorite
8:00 AM – 6:00 PM
CEST
(087) Association of Substance Use Disorder and Risk of COVID-19-related Outcomes Among Adults in Hong Kong
Favorite
8:00 AM – 6:00 PM
CEST
(088) Capturing Information Not Presented in Hazard Ratios: The Added Value of Presenting Plots of Instantaneous Hazards for Time-To-Event Analyses
Favorite
8:00 AM – 6:00 PM
CEST
(089) Characterisation of ICNARC COVID-19 data
Favorite
8:00 AM – 6:00 PM
CEST
(090) Characteristics of Registered Clinical Trials Investigating Therapeutic Interventions for Long COVID
Favorite
8:00 AM – 6:00 PM
CEST
(091) Characterization of select laboratory test in administrative healthcare data and data from commercial laboratories among patients with COVID-19 diagnosed in outpatient settings
Favorite
8:00 AM – 6:00 PM
CEST
(092) Characterizing Post-COVID Muscle Weakness Using Structured and Unstructured Electronic Health Records
Favorite
8:00 AM – 6:00 PM
CEST
(093) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in lactating women.
Favorite
8:00 AM – 6:00 PM
CEST
(094) Concomitant prescribing of nirmatrelvir/ritonavir (NMV-r) and medications with potential risk for drug-drug interaction – a feasibility assessment of Truveta Electronic Health Records Database.
Favorite
8:00 AM – 6:00 PM
CEST
(095) COVID-19 Lockdown and the Osteoporosis Treatment Among US Medicare Enrollees Who Initiated Romosozumab
Favorite
8:00 AM – 6:00 PM
CEST
(096) COVID-19 Pandemic and the Consumption of Self-Care Products for Pediculosis Capitis in Portugal: An Interrupted Time-Series Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(097) COVID-19 Related Changes in Healthcare Utilization Among Insured Persons in the US and its Impact on Pharmacoepidemiologic Research
Favorite
8:00 AM – 6:00 PM
CEST
(098) Dispensing Patterns of Inhaled Asthma Medication Before and During COVID-19 Among Young Adults: A Retrospective Inception Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(099) Distinguishing Hospital Encounters as "with" vs "for" COVID-19 Using A Large US Administrative Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(100) Drug Shortages in the U.S. and Canada Prior to and During the COVID-19 Pandemic: A Multi-National, Cross-Sectional Study
Favorite
8:00 AM – 6:00 PM
CEST
(101) Effectiveness of pre-pregnancy maternal SARS-CoV-2 vaccination in preventing COVID-19 in infants
Favorite
8:00 AM – 6:00 PM
CEST
(102) Evaluation of postmenopausal hemorrhage following Moderna COVID-19 vaccines: results from surveillance data analysis and interim results from a US claims database cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(103) Evaluation of Two Methods in Minimizing Confounding by Indication Bias in Observational Research: an Example Based on Guideline-recommended COVID-19 therapies
Favorite
8:00 AM – 6:00 PM
CEST
(104) Healthcare Utilization Among People Living With Long COVID 2.5 Years After Acute COVID-19
Favorite
8:00 AM – 6:00 PM
CEST
(105) Hospital-level Variation in COVID-19 Treatment Among Hospitalized Adults in the United States: A Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(106) Impact of allergic conditions on COVID-19 susceptibility and outcomes
Favorite
8:00 AM – 6:00 PM
CEST
(107) Impact of the COVID-19 pandemic and control measures on screening and diagnoses of type 2 diabetes in British Columbia
Favorite
8:00 AM – 6:00 PM
CEST
(108) Impact of Treatment of COVID-19 with Sotrovimab on Post-Acute COVID-19 Syndrome: An Analysis of National COVID Cohort Collaborative (N3C) Data
Favorite
8:00 AM – 6:00 PM
CEST
(109) Incidence Rate of Long COVID Among Overweight or Obese Adults Who Had COVID-19 Infection in the United Kingdom
Favorite
8:00 AM – 6:00 PM
CEST
(110) Influenza and SARS-CoV-2 coinfection: A Rapid Review of Epidemiological Literature 2020-2023
Favorite
8:00 AM – 6:00 PM
CEST
(111) Inhaled corticosteroid use associated with severity of COVID-19 diagnosis among patients with asthma, a cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(112) Investigating Previous Antibiotic Exposure Patterns among COVID-19 Hospitalised Patients: An OpenSAFELY Matched Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(113) Investigation of the Consumption Trend of Inhalants Used in the Treatment of Obstructive Airway Diseases During the COVID-19 Pandemic
Favorite
8:00 AM – 6:00 PM
CEST
(114) New Medication Use in Post-Acute Sequelae Of COVID-19 (PASC): An EHR-based Study From the RECOVER Program
Favorite
8:00 AM – 6:00 PM
CEST
(115) Nirmatrelvir and Ritonavir (Paxlovid) Prognostication: Unveiling Utilization Trends with Neural Network Time Series Forecasting
Favorite
8:00 AM – 6:00 PM
CEST
(116) Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe Covid-19: An Analysis of the National Covid Cohort Collaborative (N3C)
Favorite
8:00 AM – 6:00 PM
CEST
(117) Outcomes in patients hospitalized with severe COVID-19 treated with add-on immunomodulatory agents
Favorite
8:00 AM – 6:00 PM
CEST
(118) Patient factors associated with effectiveness of nirmatrelvir and ritonavir in prevention of Covid-19 hospitalization or death
Favorite
8:00 AM – 6:00 PM
CEST
(119) Performance of the US Food and Drug Administration’s COVID-19 Disease Severity Categorization for Use in Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(120) Post-COVID Conditions: Prevalence and Associated Factors in Individuals with Intellectual Disabilities in Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(121) Potential for Differential Outcome Misclassification in United States Claims Data during the COVID-19 Era: An Applied Example
Favorite
8:00 AM – 6:00 PM
CEST
(122) Prenatal-, Birth- and Post-Partum- Related Experiences among Women who were Pregnant in First Three Waves of the COVID-19 Pandemic in Canada: a Study Within the CONCEPTION Cohort.
Favorite
8:00 AM – 6:00 PM
CEST
(123) Racial and language disparities in initial COVID-19 vaccination during lactation
Favorite
8:00 AM – 6:00 PM
CEST
(124) Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation
Favorite
8:00 AM – 6:00 PM
CEST
(125) Reproducibility of computable phenotypes for post-acute sequelae of COVID-19 (PASC) in US administrative claims data
Favorite
8:00 AM – 6:00 PM
CEST
(126) Risk Factors for Long-Term Cardiovascular Post-Acute Sequelae of COVID-19 Infection: a Nested Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(127) Risk factors for severe outcomes among patients hospitalized with COVID-19 in US Medicare between December 2020 and March 2023
Favorite
8:00 AM – 6:00 PM
CEST
(128) Safety of Moderna mRNA-1273.214 and mRNA-1273.222 COVID-19 bivalent vaccines: results from post-marketing surveillance in South Korea
Favorite
8:00 AM – 6:00 PM
CEST
(129) Safety of Moderna’s mRNA-1273.222 bivalent omicron-containing vaccine: interim results from a US claims database cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(130) School Closures and Prescription Medication Use Among Children and Adolescents Before and During the COVID-19 Pandemic in the United States, 2019-2022
Favorite
8:00 AM – 6:00 PM
CEST
(131) Survival of critically ill COVID-19 patients in Sweden during the first two-and-a-half years of the pandemic
Favorite
8:00 AM – 6:00 PM
CEST
(132) The Association Between Asthma and Outcomes of COVID-19
Favorite
8:00 AM – 6:00 PM
CEST
(133) The Comparative Effectiveness of Baricitinib And Tocilizumab in Hospitalized Patients With Covid: A Retrospective Cohort Study of The National Covid Cohort Collaborative (N3C)
Favorite
8:00 AM – 6:00 PM
CEST
(134) The Impact of COVID-19 Containment Strictness on the Administration of Romosozumab among Medicare Enrollees in the Most Socioeconomically Vulnerable Counties in the US
Favorite
8:00 AM – 6:00 PM
CEST
(135) The Impact of COVID-19 Pandemic on Alcohol Dependence Treatment in Portugal: a Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(136) The Impact of COVID-19 Pandemic on the Consumption of Anti-hypertensive, Anti-diabetes and Anti-hyperlipidemic Medications.
Favorite
8:00 AM – 6:00 PM
CEST
(137) The impact of prenatal maternal depression during the COVID-19 pandemic on maternal postpartum depression: A prospective cohort study within the CONCEPTION study.
Favorite
8:00 AM – 6:00 PM
CEST
(138) The risks of immune- and inflammatory related post-acute sequelae of COVID-19: a network study in 6 European countries, the US, and Korea
Favorite
8:00 AM – 6:00 PM
CEST
(139) Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic
Favorite
8:00 AM – 6:00 PM
CEST
(140) Use of Ursodeoxycholic Acid and the Risk of Long COVID in Patients with Steatotic Liver Disease
Favorite
8:00 AM – 6:00 PM
CEST
(141) A Cross-Sectional Observational Study to Assess Treatment Awareness, Prescription Pattern and Adverse Drug Reactions of Secondary Prophylactic Drug Treatment in Patients of Stroke visiting a Tertiary Care Hospital.
Favorite
8:00 AM – 6:00 PM
CEST
(142) A multi-country, observational study of high-risk pre-event cardiovascular patients: design and analytical framework
Favorite
8:00 AM – 6:00 PM
CEST
(143) A Population-Based Assessment of the Use of Oral Anticoagulants and the Risk of Major Bleeding Among Patients with Non-Valvular Atrial Fibrillation Treated With Antiarrhythmics
Favorite
8:00 AM – 6:00 PM
CEST
(144) A scoping Review of Factors Associated with the Prescribing of Direct Oral Anticoagulant Drugs (DOACs)
Favorite
8:00 AM – 6:00 PM
CEST
(145) Acute cardiovascular adverse effects associated with the use of prescription medications: A Danish nationwide screening study
Favorite
8:00 AM – 6:00 PM
CEST
(146) An Electronic Health Record Analysis Studying Differences in Medication Use Associated with Renal Impairment in Acute Heart Failure
Favorite
8:00 AM – 6:00 PM
CEST
(147) Antiplatelet Drug Utilization Trends in Hungary from 2012 to 2022
Favorite
8:00 AM – 6:00 PM
CEST
(148) Association between incident interstitial lung disease with direct oral anticoagulants compared to warfarin users: Multi-database cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(149) Characteristics Associated with Long-Term Glucocorticoid Use in Patients with New Onset Polymyalgia Rheumatica
Favorite
8:00 AM – 6:00 PM
CEST
(150) Associations between β-adrenoreceptors agonists and antagonists and Parkinson’s disease: systematic review and meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(151) Case Study With a Cardiovascular Outcomes Trial for a Glucagon-Like Peptide-1 Receptor Agonist: Evaluating Trial Generalizability With an Enriched Electronic Health Record-Based Database
Favorite
8:00 AM – 6:00 PM
CEST
(152) Characterizing Patients with Postural Orthostatic Tachycardia Syndrome (POTS) in Claims Data After the Introduction of a Specific Diagnosis Code
Favorite
8:00 AM – 6:00 PM
CEST
(154) Comparative cardiovascular safety evaluation of long- vs short-acting erythropoiesis-stimulating agents (ESA) in chronic kidney disease patients: a meta-analysis and signal detection using the FDA Adverse Event Reporting System
Favorite
8:00 AM – 6:00 PM
CEST
(155) Comparative effectiveness and prescribing trends of modified-release versus immediate-release indapamide in patients with hypertension: a cohort study in the UK
Favorite
8:00 AM – 6:00 PM
CEST
(156) Comparative Effectiveness and Safety of High-Intensity Statin Monotherapy vs. Combination Therapy with Ezetimibe in Post-ACS Lipid Management in Asian Patients: An Observational Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(157) Comparative effectiveness of anti-hyperlipidemic drugs monotherapy in primary prevention of cardiovascular disease
Favorite
8:00 AM – 6:00 PM
CEST
(158) Comparative Effectiveness of ARB and ACEi for Cardiovascular Outcomes and Risk of Angioedema by Ethnicity: an Analysis in the UK Clinical Practice Research Datalink with Emulation of a Reference Trial (ONTARGET)
Favorite
8:00 AM – 6:00 PM
CEST
(159) Comparison of rates of myocardial infarction and stroke for patients with type 2 diabetes 2005 versus 2015
Favorite
8:00 AM – 6:00 PM
CEST
(160) Cost-Effectiveness of Statins in the Primary Prevention of Cardiovascular Disease in Older Adults: A 5-Year Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(161) DARWIN EU® - Real-World Evaluation of Pulmonary Arterial Hypertension Treatment and Outcomes in Europe
Favorite
8:00 AM – 6:00 PM
CEST
(162) Decreased Hazard of Potassium Lowering Drug Prescription Receipt Following Implementation of the 2021 CKD-EPI Creatinine GFR Equation
Favorite
8:00 AM – 6:00 PM
CEST
(163) Disseminated Intravascular Coagulation after idarucizumab or andexanet alfa: a disproportional analysis and case-by-case analysis of reports from the FAERS database
Favorite
8:00 AM – 6:00 PM
CEST
(164) Early identification of the association between rofecoxib and cardiovascular adverse events using real-world data from the UK: A case-control study
Favorite
8:00 AM – 6:00 PM
CEST
(165) Effectiveness of early versus delayed post-discharge sodium-glucose cotransporter-2 inhibitor initiation in acute heart failure with type 2 diabetes: a population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(166) Effectiveness, Safety, and Mortality of Cilostazol versus Clopidogrel in East Asian Patients with Ischemic Stroke and Transient Ischemic Attack
Favorite
8:00 AM – 6:00 PM
CEST
(167) Evaluating Algorithms for Sinus Node Dysfunction in US Health Insurance Claims Databases
Favorite
8:00 AM – 6:00 PM
CEST
(168) Evaluating the Cardiovascular Safety of Naltrexone/Bupropion in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(169) Exploration of Reason Codes in Real World Cardiovascular System Short-term Disability Claims in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(170) FACTOR XA INHIBITOR–RELATED MAJOR BLEEDING EVENTS IN THE NETHERLANDS
Favorite
8:00 AM – 6:00 PM
CEST
(171) Factors Associated with Reinitiation and Subsequent Discontinuation of Antiplatelet Medication in Patients with Peripheral Arterial Disease
Favorite
8:00 AM – 6:00 PM
CEST
(172) Feasibility Assessment of Hypertension among Patients with Diabetic Macular Edema using Real World Data
Favorite
8:00 AM – 6:00 PM
CEST
(173) Identifying and profiling patients with heart failure in a population-based cohort through linkage of primary and secondary care data
Favorite
8:00 AM – 6:00 PM
CEST
(174) Impact of Cardiovascular Medications on Non-Traumatic Amputation Rates in Type 2 Diabetes: Insights from a Large-Scale Retrospective Real-World Data Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(175) Implementation and Evaluation of Medication Therapy Management in Patients with Hypertension
Favorite
8:00 AM – 6:00 PM
CEST
(176) Incidence of Heat-Related Illness in the United States: A Retrospective Cohort Study Using the PharMetrics® Plus for Academics Dataset, 2017-2022
Favorite
8:00 AM – 6:00 PM
CEST
(177) Indapamide-Induced Rhabdomyolysis: A Retrospective Analysis of Electronic Health Records
Favorite
8:00 AM – 6:00 PM
CEST
(178) Lasso Logistic Regression and Cluster Analysis in Predicting Adherence and Drug Patterns among New Users of Monotherapy for Antihypertensive Drugs: a long-term inception cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(179) Low-density Lipoprotein Measurement During and After Hospitalization with Myocardial Infarction in Denmark from 2018 to 2021.
Favorite
8:00 AM – 6:00 PM
CEST
(180) Mapping of Knowledge, Attitude & Practice in Patients Toward Cardiovascular Disorders Attending Out-Patient Department of Cardiology in a Tertiary Care Hospital
Favorite
8:00 AM – 6:00 PM
CEST
(181) Medication adherence and its association with blood pressure control at a teaching hospital in Ghana
Favorite
8:00 AM – 6:00 PM
CEST
(182) Oral anticoagulant prescription trends and adherence among patients with atrial fibrillation and mitral stenosis in Hong Kong
Favorite
8:00 AM – 6:00 PM
CEST
(183) Outcomes of antiarrythmic drugs versus catheter ablation for treatment of atrial fibrillation in an elderly population
Favorite
8:00 AM – 6:00 PM
CEST
(184) Patterns and Determinants of Adherence to Medication Guideline in Myocardial Infarction (MI) Survivors: A Retrospective Cohort Study of 21,510 patients
Favorite
8:00 AM – 6:00 PM
CEST
(185) Predicting Findings of Two On-Going Phase IV Randomized Trials of Direct Oral Anticoagulants: An RCT-DUPLICATE Study.
Favorite
8:00 AM – 6:00 PM
CEST
(186) Real-World Patient Profiles and Lipid-Lowering Efficacy of PCSK9 Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(187) Real-World Safety and Effectiveness of Evolocumab in Primary Hypercholesterolemia and Mixed Dyslipidemia in Saudi Arabia
Favorite
8:00 AM – 6:00 PM
CEST
(188) Renal outcomes of cyclooxygenase-2 inhibitor anti-inflammatories: a systematic review and meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(189) Risk identification based on prescribed drugs and comorbidities in patients with Torsade de pointes arrhythmia – a population-based Swedish cohort study.
Favorite
8:00 AM – 6:00 PM
CEST
(190) Risk of Lung Cancer With Concomitant Use of Angiotensin Converting Enzyme Inhibitors and Dipeptidyl Peptidase 4 Inhibitors: Population Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(191) Sex differences in dispensed cardiovascular medication in primary care
Favorite
8:00 AM – 6:00 PM
CEST
(192) Shifting Patterns in Statin Intensity During Post-Acute Coronary Syndrome Period: An Nationwide Observational Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(193) Temporal Trends In The Dispensing Of Anti-Hypertensive Medications In Ireland And The United Kingdom From 2017-2023
Favorite
8:00 AM – 6:00 PM
CEST
(194) The Impact of National Volume-Based Procurement Program Implementation on Medical Expenditures in China: A Population-based Study of 1.17 Million Hypertensive Patients
Favorite
8:00 AM – 6:00 PM
CEST
(195) The use of Gastroprotective Agents in Patients with Atrial Fibrillation Initiating Direct Oral Anticoagulants
Favorite
8:00 AM – 6:00 PM
CEST
(196) Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease – a Multi-Country Report from the FOUNTAIN Platform
Favorite
8:00 AM – 6:00 PM
CEST
(197) Using negative control outcomes in trial emulation to assess the comparability of patients initiating proprotein convertase subtilisin/kexin type 9 inhibitor monoclonal antibodies following myocardial infarction
Favorite
8:00 AM – 6:00 PM
CEST
(198) Utilisation Patterns and Trends of Statins in Kuwait from 2012 to 2022: A Population-Based Study
Favorite
8:00 AM – 6:00 PM
CEST
(199) Analysis of New Molecular Entity Utilization Patterns using the Sentinel Distributed Database
Favorite
8:00 AM – 6:00 PM
CEST
(200) Developing a drug shortages predictive model using real-world Canadian drug utilization
Favorite
8:00 AM – 6:00 PM
CEST
(201) Drug Utilisation Study of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-authorisation Safety Study
Favorite
8:00 AM – 6:00 PM
CEST
(202) Fear of Missing Out: Drug Availability in Canada versus the USA
Favorite
8:00 AM – 6:00 PM
CEST
(203) Medicine utilisation studies in Australian individual-level dispensing data: A blinded, multi-centre replication experiment
Favorite
8:00 AM – 6:00 PM
CEST
(204) Off-label drug prescriptions in Latin America: a systematic review
Favorite
8:00 AM – 6:00 PM
CEST
(205) Osteoporosis treatment patterns in France: A Clustering Analysis of the SNDS PMO Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(206) Patient characteristics associated with Topical Calcineurin Inhibitor Discontinuation: A retrospective cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(207) Patterns and Associated Factors with Emergency Department Visit due to Drug Poisoning in Korea
Favorite
8:00 AM – 6:00 PM
CEST
(208) Pharmacovigilance Analysis of Immune-Related Adverse Effects to Uncover Repurposable Drugs for Hepatocellular Carcinoma
Favorite
8:00 AM – 6:00 PM
CEST
(209) Potentially drug-related emergency hospital admissions and their influence on patient's long-term medication. Analysis of administrative data from a Scottish Database.
Favorite
8:00 AM – 6:00 PM
CEST
(210) Prevalence and Predictors for potentially Adverse Drug Event-related Hospitalisations
Favorite
8:00 AM – 6:00 PM
CEST
(211) Prevalence of Medication-Related Risk Factors for Adverse Drug Reactions
Favorite
8:00 AM – 6:00 PM
CEST
(212) Regional variations in the use of thyroid stimulating hormone measurements and levothyroxine in Germany: a small area analysis based on claims data
Favorite
8:00 AM – 6:00 PM
CEST
(213) Temporal trend in the commercialization of selective cyclooxygenase-2 inhibitors in drugstores in Brazil from 2014 to 2021
Favorite
8:00 AM – 6:00 PM
CEST
(214) Treatment patterns in patients with dermatomyositis in the United Kingdom: a cohort study using the Clinical Practice Research Datalink
Favorite
8:00 AM – 6:00 PM
CEST
(215) Use of intravenous iron between 2004 and 2019 in Germany overall and in pregnant women
Favorite
8:00 AM – 6:00 PM
CEST
(216) Use of leukotriene receptor antagonists (LTRAs) among patients with asthma in the UK primary care
Favorite
8:00 AM – 6:00 PM
CEST
(217) 5-alpha Reductase Inhibitors and Effects on Auditory System in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(218) Assessing Environmental Risks Associated with Contraceptives: A Multi-Scenario Approach
Favorite
8:00 AM – 6:00 PM
CEST
(219) What motivates patients with chronic musculoskeletal pain to use medical cannabis as a treatment strategy? Results from a questionnaire study.
Favorite
8:00 AM – 6:00 PM
CEST
(220) Common Mental Health Diagnoses Arising from or Coinciding with Menopausal Transition and Prescribing of SSRIs/SNRIs and Other Psychotropic Medications
Favorite
8:00 AM – 6:00 PM
CEST
(221) Levonorgestrel-releasing Intrauterine Systems And Copper Intrauterine Devices Utilization In France: Changes From The Last Decade
Favorite
8:00 AM – 6:00 PM
CEST
(222) Menopausal hormone therapy and colorectal cancer recurrence and mortality: a Danish population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(223) Real World Retrospective Analysis of Short-term Disability Claims for Genitourinary System Conditions in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(224) Study of utilization of oral contraceptive drugs & relevant perceptions of general population in Greece with the use of a questionnaire
Favorite
8:00 AM – 6:00 PM
CEST
(225) Unveiling the Impact of Spironolactone in Women with PCOS: Beyond Its Anti-androgen Properties - Insights from a Systematic Review and Meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(226) Use of progestogens and the risk of intracranial meningioma: a national case-control study
Favorite
8:00 AM – 6:00 PM
CEST
(227) A Comprehensive Analysis to Unravel Antimicrobial Usage Patterns on a Global Scale: Decoding A Decade (2013-2022)
Favorite
8:00 AM – 6:00 PM
CEST
(228) A Cross-Sectional Observational Study to Assess Prescription Pattern, Awareness of Parents regarding Disease and Use of Antimicrobial agents and Cost of treatment in Children Admitted in a Tertiary Care Hospital.
Favorite
8:00 AM – 6:00 PM
CEST
(229) A national point prevalence survey to assess surgical antibiotic prophylaxis duration and timing in obstetrics and gynaecological surgery in Kuwait
Favorite
8:00 AM – 6:00 PM
CEST
(230) A pragmatic randomized trial assessing the impact of peer comparison and therapeutic recommendations on antibiotic prescribing patterns of family physicians for uncomplicated lower urinary tract infections
Favorite
8:00 AM – 6:00 PM
CEST
(231) Adverse drug reactions due to antitubercular therapy in multidrug resistant tuberculosis in North east India
Favorite
8:00 AM – 6:00 PM
CEST
(232) Antibiotic Exposure of Pediatric Patients: Local Study from an Urgent Care Clinic
Favorite
8:00 AM – 6:00 PM
CEST
(233) Antibiotic use and risk of microscopic colitis in older adults: a nationwide self-controlled case series study
Favorite
8:00 AM – 6:00 PM
CEST
(234) Antiretroviral Initiation and Adherence between Transgender and Cisgender Medicaid Beneficiaries with HIV
Favorite
8:00 AM – 6:00 PM
CEST
(235) Antitubercular Therapy Associated Gut Microbiota Dysbiosis in Pulmonary Tuberculosis: A Computational Analysis from Open Datasets
Favorite
8:00 AM – 6:00 PM
CEST
(236) Assessing Antibiotic Prescribing Patterns in Private Outpatient Settings: A WHO AWaRe Classification Analysis in a Jeddah Polyclinic
Favorite
8:00 AM – 6:00 PM
CEST
(237) Assessment of Surgical Antibiotic Prophylaxis Appropriateness in Obstetrics and Gynaecological Surgery in Kuwait: A National Point Prevalence Survey
Favorite
8:00 AM – 6:00 PM
CEST
(238) Association between repeated antibiotic prescribing and hospitalization among people living with dementia: a population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(239) Background Incidence Rates of Guillain-Barre Syndrome in United States Older Adults at Risk of Respiratory Syncytial Virus in a Trial-Similar Real World Data Cohort
Favorite
8:00 AM – 6:00 PM
CEST
(240) Ceftazidime-avibactam versus Colistin in the treatment of Carbapenem-Resistant Enterobacteriaceae infections
Favorite
8:00 AM – 6:00 PM
CEST
(241) Clinical manifestations, complications, and healthcare utilization of adult outpatients with RSV infection in the United States: a retrospective real-word study
Favorite
8:00 AM – 6:00 PM
CEST
(242) Clostridioides difficile Infection in South Korea: Retrospective Study on Annual Incidence Rates and Treatment Status
Favorite
8:00 AM – 6:00 PM
CEST
(243) Comorbidities and Numbers of Drugs Prescribed Influence the Potential Drug Interactions in Pulmonary Tuberculosis Patients in A Public Hospital in Banjarmasin, Indonesia
Favorite
8:00 AM – 6:00 PM
CEST
(244) Comparative Effect of Four Antimalarial Treatments on Haematocrit in Children in Southwest, Nigeria.
Favorite
8:00 AM – 6:00 PM
CEST
(245) Comparative Effectiveness of Single-Drug Versus Vancomycin-based Combination Antimicrobial Regimens in Post-Neurosurgical Infections at a Northwest China Hospital
Favorite
8:00 AM – 6:00 PM
CEST
(246) Comparative Postmarketing Safety Assessment of Baloxavir Marboxil vs Oseltamivir using TreeScan™
Favorite
8:00 AM – 6:00 PM
CEST
(247) DARWIN EU® - Characterization of Patients with Chronic Hepatitis B and C
Favorite
8:00 AM – 6:00 PM
CEST
(248) Data mining of adverse reactions of antimicrobial agents leading to coagulation disorders based on FAERS database
Favorite
8:00 AM – 6:00 PM
CEST
(249) Decreased risk of clinical gallstone disease after antibiotics that kill or inhibit 7α-dehydroxylating-bacteria
Favorite
8:00 AM – 6:00 PM
CEST
(250) Disparities In Direct-Acting Antiviral Agents Uptake And Mortality Among Patients With HCV-Related HCC
Favorite
8:00 AM – 6:00 PM
CEST
(251) Dynamic containment strategy in critical ill patients with high risk of antibiotic drug resistance, a MIMIC-IV study
Favorite
8:00 AM – 6:00 PM
CEST
(252) Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors vs dipeptidyl peptidase 4 inhibitors on liver outcomes in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
Favorite
8:00 AM – 6:00 PM
CEST
(254) Enhancing US Lyme Disease Detection in Claims Data: Identifying Acute and Disseminated Disease
Favorite
8:00 AM – 6:00 PM
CEST
(255) Evaluating the Cardioprotective Effects of Antivirals in Influenza Patients: A Retrospective Cohort Study.
Favorite
8:00 AM – 6:00 PM
CEST
(256) Evaluation of Antimicrobial Stewardship Metrics in General Surgery Wards
Favorite
8:00 AM – 6:00 PM
CEST
(257) Evaluation of different ARIMA models incorporating the impact of COVID-19 for the forecasting of the prescription rates of antibiotics in the UK between 2013 to 2023
Favorite
8:00 AM – 6:00 PM
CEST
(258) Evaluation of the Vaccinated Concurrent Comparator Methodology for Near Real Time Safety Surveillance
Favorite
8:00 AM – 6:00 PM
CEST
(259) Exploring the Effects of COVID-19 on Antibiotic Consumption Patterns in Iran’s Outpatient Setting: A Cross-Sectional Study
Favorite
8:00 AM – 6:00 PM
CEST
(260) Fluoroquinolones and the risk of aortic aneurysm or dissection: a cohort study in German health claims data
Favorite
8:00 AM – 6:00 PM
CEST
(261) Framework for Public-Private Partnerships for Real-World Data Exchange of Immunizations Records for Public Health Surveillance
Favorite
8:00 AM – 6:00 PM
CEST
(262) Frequency and Duration of Antibiotic Shortages: A Global Comparison
Favorite
8:00 AM – 6:00 PM
CEST
(263) Human albumin for adults with sepsis: an updated systematic review and meta-analysis of randomized controlled trials
Favorite
8:00 AM – 6:00 PM
CEST
(264) Human papillomavirus vaccination among Adolescents and Young Adults who have been treated for cancer: a matched comparative cohort study from the French National Health Data System
Favorite
8:00 AM – 6:00 PM
CEST
(265) id.DRIVE: a Public-Private Partnership for Burden and Effectiveness Studies on Infectious Diseases, Vaccines, Related Preventive Measures and Therapeutics in Europe.
Favorite
8:00 AM – 6:00 PM
CEST
(266) Identifying Potential Drug Interactions in Kidney-Impaired Individuals Co-infected with Human Immunodeficiency Virus and Malaria in Lagos: A Focus for Enhancing Treatment Strategies.
Favorite
8:00 AM – 6:00 PM
CEST
(267) Impact of medication adherence to active tuberculosis occurrence in pediatric population with latent tuberculosis infection: A population-based cohort study in South Korea
Favorite
8:00 AM – 6:00 PM
CEST
(268) Impact of National Public-Private Mix and Medical Expense Support Program for Control Tuberculosis in South Korea: An Interrupted Time Series Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(269) Impact of Obesity on Clinical and Economic Outcomes in Hospitalized Patients with Skin and Subcutaneous Tissue Infections Receiving Systemic Antibacterial Therapy in Korea
Favorite
8:00 AM – 6:00 PM
CEST
(270) Knowledge Attitude and Practice of Obstetricians and Gynaecologists towards appropriate surgical antibiotic prophylaxis prescribing in Obstetric and gynaecological surgery in Kuwait: A national cross-sectional survey
Favorite
8:00 AM – 6:00 PM
CEST
(271) Knowledge, attitude, and practices of pharmacy students in seven Middle Eastern countries concerning antimicrobial resistance
Favorite
8:00 AM – 6:00 PM
CEST
(272) Liver Enzymes During and After Antimalarial Therapy with Artemether-Lumefantrine in Nigerian Children with Uncomplicated Plasmodium Falciparum Infection.
Favorite
8:00 AM – 6:00 PM
CEST
(273) Medicine use in children aged under 12 years in Serbia: a focus on antibiotics
Favorite
8:00 AM – 6:00 PM
CEST
(274) Oral Antibiotic Shortages and Their Impact on Drug Utilization in Australia
Favorite
8:00 AM – 6:00 PM
CEST
(275) Outpatient Use of Antibiotics in Iran: A National study using claim data from 2014 to 2019
Favorite
8:00 AM – 6:00 PM
CEST
(276) Over-the-counter sales of high-priority antibiotics is common: results of a global survey
Favorite
8:00 AM – 6:00 PM
CEST
(278) Patients’ Knowledge, Attitude, And Practices of Self-Medication with Antibiotics
Favorite
8:00 AM – 6:00 PM
CEST
(279) Post-Marketing Safety Surveillance of Vaccines in Japan for Older Adults: A Feasibility Assessment of Real-World Data Capabilities
Favorite
8:00 AM – 6:00 PM
CEST
(280) Post-marketing surveillance for the safety of the 4-valent human papillomavirus (HPV) vaccine in China: a retrospective real-world study
Favorite
8:00 AM – 6:00 PM
CEST
(281) Prevalence and Patterns of Antibiotic Prophylaxis in Kuwaiti Obstetric and Gynaecological Surgery: A National Point Prevalence Survey
Favorite
8:00 AM – 6:00 PM
CEST
(282) Progress toward implementation of national antimicrobial resistance action plans, including use of the internet
Favorite
8:00 AM – 6:00 PM
CEST
(283) Recurrence of Diabetic Foot Complications: A Domino Effect Leading to Lethal Consequences - Insights from a National Longitudinal Study
Favorite
8:00 AM – 6:00 PM
CEST
(284) Retrospective Cross-Sectional Study Assessing Adverse Events And Treatment Failure In Pediatric Hemato-Oncological Patients Receiving Posaconazole (Off-label) Or Liposomal Amphotericin B Prophylaxis
Favorite
8:00 AM – 6:00 PM
CEST
(285) Risk Factors of Antimicrobial Resistance in Patients with Pneumococcal Infection in Hong Kong – a Population-based Unmatched Case-control Study
Favorite
8:00 AM – 6:00 PM
CEST
(286) Safety of the Use of Fluoroquinolone Antibiotics in Patients with Kidney Disease
Favorite
8:00 AM – 6:00 PM
CEST
(287) Safety Results of Post-Marketing Surveillance Studies of B/F/TAF in China and South Korea
Favorite
8:00 AM – 6:00 PM
CEST
(288) Self-test as a strategy to promote HIV testing among men who have sex with men and transgender women - overview of systematic reviews and meta-analyses
Favorite
8:00 AM – 6:00 PM
CEST
(289) Serotype Distribution, Antibiotics Use, and Antimicrobial Resistance in Paediatric Patients with Pneumococcal Infection in Hong Kong – a Population-based Study
Favorite
8:00 AM – 6:00 PM
CEST
(290) The Effect of antibiotics prescription and length of hospitalization on mortality in patients with systemic infections
Favorite
8:00 AM – 6:00 PM
CEST
(291) The HAPPY PATIENT Project: Measuring and Improving Community Antibiotic Dispensing in Europe
Favorite
8:00 AM – 6:00 PM
CEST
(292) The role of Rheumatic Diseases in the relationship between mRNA vaccines and Myocarditis/Pericarditis in a cohort of Italian vaccinees: TheShinISS-Vax Study
Favorite
8:00 AM – 6:00 PM
CEST
(293) Time trends of prevalence of drugs with suggested shortages in Europe
Favorite
8:00 AM – 6:00 PM
CEST
(294) Urinary tract infection diagnosis and management in eight European countries: Results of a context analysis study.
Favorite
8:00 AM – 6:00 PM
CEST
(295) Use of antibacterials and suspected acute renal failure in Brazil: pharmacovigilance analysis, 2018-2023
Favorite
8:00 AM – 6:00 PM
CEST
(296) Use of Non-Specific Immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry
Favorite
8:00 AM – 6:00 PM
CEST
(297) Use of systemic fluoroquinolones in primary care and hospital settings in the UK: A population-level cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(298) A nationwide study of psychotherapy treatment at Danish psychiatric clinics
Favorite
8:00 AM – 6:00 PM
CEST
(299) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of paliperidone, risperidone, and low-energy fracture
Favorite
8:00 AM – 6:00 PM
CEST
(300) Antipsychotics in treatment of adolescents with schizophrenia in China
Favorite
8:00 AM – 6:00 PM
CEST
(301) Anxiety Disorders Diagnosed in Outpatient Encounters Among Commercially Insured US Adults
Favorite
8:00 AM – 6:00 PM
CEST
(302) Assessment of Polypharmacy And Potentially Inappropriate Medication Use Among Psychiatric Patients: A Prospective Study.
Favorite
8:00 AM – 6:00 PM
CEST
(303) Benzodiazepine receptor agonists and increased risk of sudden sensorineural hearing loss
Favorite
8:00 AM – 6:00 PM
CEST
(304) Brain derived Neurotrophic factor (BDNF): A potential biomarker for seizure associated cognitive impairment in adult persons with epilepsy (PWE)
Favorite
8:00 AM – 6:00 PM
CEST
(305) Daridorexant and sleeping disorders: comparative study with sleeping medication (zopiclone, oxazepam).
Favorite
8:00 AM – 6:00 PM
CEST
(306) Development of matching procedures to identify comparators for real-world comparative evaluations of antipsychotics
Favorite
8:00 AM – 6:00 PM
CEST
(307) Efficacy and safety of riluzole in the treatment of Amyotrophic Lateral Sclerosis, a population based study in Italy
Favorite
8:00 AM – 6:00 PM
CEST
(308) Evaluation Epilepsy Patterns and Treatment Approaches: Findings from a Neurological Tertiary Care Hospital
Favorite
8:00 AM – 6:00 PM
CEST
(309) Examining the impact of benzodiazepine formulary restrictions on benzodiazepine-related harms in a Medicaid population, 2004-2016
Favorite
8:00 AM – 6:00 PM
CEST
(310) Fatal intoxications with zopiclone and alprazolam in Sweden during 2012-2020 – a register-based study
Favorite
8:00 AM – 6:00 PM
CEST
(311) Generalized anxiety disorder: Epidemiology, burden, and comorbid depression.
Favorite
8:00 AM – 6:00 PM
CEST
(312) Identifying Longitudinal Medication Adherence Patterns of Antipsychotic Treatments; A Real-World Cohort Study in Catalonia, Spain.
Favorite
8:00 AM – 6:00 PM
CEST
(313) Influence of unemployment on antidepressant sales in drugstores in Brazil: time series analysis, 2014-2021
Favorite
8:00 AM – 6:00 PM
CEST
(314) Mapping the Epidemiological burden of active and lifetime epilepsy in Asian Countries: A Systematic review and Meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(315) Post-discharge Use of Antipsychotics in Patients with Hospital-acquired Delirium and Associated Risk of Mortality – A Target Trial Emulation Framework Study
Favorite
8:00 AM – 6:00 PM
CEST
(316) Potential Association of Syndrome of Inappropriate Antidiuretic Hormone Secretion with Olanzapine Use
Favorite
8:00 AM – 6:00 PM
CEST
(317) Psychotropic medicine use in the German National Cohort (NAKO) baseline
Favorite
8:00 AM – 6:00 PM
CEST
(318) Safety and efficacy of second-generation antipsychotics in Autism Spectrum Disorder: a systematic review and network meta-analysis
Favorite
8:00 AM – 6:00 PM
CEST
(319) The risk of myocarditis, cardiomyopathy and cutaneous vasculitis associated with quetiapine in patients with schizophrenia and bipolar disorder.
Favorite
8:00 AM – 6:00 PM
CEST
(320) Therapeutic strategies after discontinuation of valproate in clinical practice in women with bipolar disorder: a cohort study in the United Kingdom and France databases
Favorite
8:00 AM – 6:00 PM
CEST
(321) Therapeutic strategies after discontinuation of valproate in clinical practice in women with epilepsy: a cohort study in the United Kingdom and France databases
Favorite
8:00 AM – 6:00 PM
CEST
(322) Trends in gabapentinoid prescribing: a nationwide Danish drug utilization study
Favorite
8:00 AM – 6:00 PM
CEST
(323) Trends In Psychotropic Medication Utilisation in Community Pharmacies In Chile Between 2018 - 2022
Favorite
8:00 AM – 6:00 PM
CEST
(324) Utilization of Antiparkinsonian Medication in Romania over 25 years
Favorite
8:00 AM – 6:00 PM
CEST
(325) Utilization of Psychotropic Medications Among Patients Diagnosed with Glioma: A Multinational Drug Utilisation Study
Favorite
8:00 AM – 6:00 PM
CEST
(326) Anti-epileptic Drugs Use and the Risk of Glaucoma: A population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(327) Characteristics of a population using anti-glaucoma therapy in the UK CPRD GOLD
Favorite
8:00 AM – 6:00 PM
CEST
(328) Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark – A observational registry study of 30,100 Danish patients with glaucoma
Favorite
8:00 AM – 6:00 PM
CEST
(329) Adverse Events of Drugs Used in Pain Therapies: An Analysis of Spontaneous Reports from Switzerland
Favorite
8:00 AM – 6:00 PM
CEST
(330) Analgesia Dispensing in Primary Care in Ireland and England - A Repeated Cross-Sectional Study
Favorite
8:00 AM – 6:00 PM
CEST
(331) Comparative risk of mortality in new users of prescription opioids for non-cancer pain: results from the International Pharmacosurveillence Study
Favorite
8:00 AM – 6:00 PM
CEST
(332) Antenatal depressive and anxiety symptoms in women with eating disorders who continue or discontinue antidepressant treatment in pregnancy - results from the Norwegian Mother, Father, and Child Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(333) Fatal intoxications with paracetamol in Sweden – a majority of fatalities had a prescription
Favorite
8:00 AM – 6:00 PM
CEST
(334) Impact of pharmacovigilance interventions targeting diclofenac on pain medication use in the United Kingdom
Favorite
8:00 AM – 6:00 PM
CEST
(335) Natural history of knee osteoarthritis with regards to other joint sites and knee replacement: a population-based cohort study in the UK Clinical Practice Research Datalink (CPRD)
Favorite
8:00 AM – 6:00 PM
CEST
(336) Prevalence and risk factors associated with adverse drug reactions to propofol used during interventional endoscopic procedures in a Peruvian population: cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(337) Prevalence, characteristics, and prescription pain medication use in the osteoarthritis population
Favorite
8:00 AM – 6:00 PM
CEST
(338) Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain
Favorite
8:00 AM – 6:00 PM
CEST
(339) Risk of lower extremity injury following concussion in the National Football League
Favorite
8:00 AM – 6:00 PM
CEST
(340) Self-reported physical functioning in patients with chronic low back pain (CLBP)
Favorite
8:00 AM – 6:00 PM
CEST
(341) Development and Evaluation of Python Language Processed Automated Disproportionality Analysis System for FAERS Database
Favorite
8:00 AM – 6:00 PM
CEST
(342) Exploration of Novel Adverse Drug Reactions of Trifluoperazine using FAERS database and Identification of Associated Genes and Proteins
Favorite
8:00 AM – 6:00 PM
CEST
(343) Identifying the Safety Signals for Adverse Events Causing Mortality Due to Ferric Carboxymaltose: A Disproportionality Analysis of Spontaneous Reports and Extensive Systematic Review
Favorite
8:00 AM – 6:00 PM
CEST
(344) Interpreting Vedolizumab: Uncovering Cachexia Signal in U.S Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Favorite
8:00 AM – 6:00 PM
CEST
(345) Medication Errors in EudraVigilance: Signals of Disproportionate Reporting Among Age Groups
Favorite
8:00 AM – 6:00 PM
CEST
(346) Novel Adverse Event of Atezolizumab: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Favorite
8:00 AM – 6:00 PM
CEST
(347) Post-marketing safety of ALK inhibitors: an analysis of EudraVigilance reports between 2012 and 2022
Favorite
8:00 AM – 6:00 PM
CEST
(348) Recent Trends in Global Adverse Event Reporting: A Descriptive Analysis of VigiBase
Favorite
8:00 AM – 6:00 PM
CEST
(349) Safety Analysis of Adverse Drug Reactions in United States: A 21-Year descriptive Study of FDA Adverse Event Reporting System
Favorite
8:00 AM – 6:00 PM
CEST
(350) Transverse Myelitis Associated with Tozinameran Use: Adverse Events- Signal
Favorite
8:00 AM – 6:00 PM
CEST
(351) Unveiling the Hidden Toll of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System.
Favorite
8:00 AM – 6:00 PM
CEST
(352) Views on The Development and Use of a New Digital Health Platform to Improve Adverse Drug Event Detection, Management and Reporting in Australia: A Qualitative Study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT01) Validity of the ICD-10-CM diagnosis code to identify patients with COVID-19 in Medicare administrative claims data
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT02) Contents of a Strong Real World Data Quality and Relevance Package for Regulatory or Health Technology Assessment Submission
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT03) The Value of Large Population-based Electronic Health Record and Insurance Claims Databases for Real-World Evidence Generation in Rare Diseases: a Systematic Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT04) Use of Fluoroquinolones and Risk of Rhegmatogenous Retinal Detachment: A Retrospective Cohort Study Using Two National Representative Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT05) Untangling National Medicaid Data: 30 Data Quality Metrics to Support Maternal Health Studies in Two Common Data Models
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT06) Comorbidity associated with COVID-19 hospitalisation among 135,000 children and adolescents with SARS-CoV-2 infection during their initial COVID-19 vaccination campaign in Spain
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT07) Exploring sources of statistical heterogeneity in a multi-database observational study: results from a case study using EXACOS-CV
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT08) Towards a Framework to Describe Diversity of Real-World Data Sources: Findings from the DIVERSE Initiative
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT09) Development of a Machine Learning Prediction Model for COVID-19 Patient Outcome Using a Sequential Data-Based Patient Similarity Metric
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT10) Evaluation of drug hypersensitivity reactions documented in a new coded and structured hypersensitivity documentation tool with de-labeling function: A retrospective cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT11) Evaluation of ablation workflow for Paroxysmal and Persistent Atrial Fibrillation Treatment using electronic health record linked with digital health data
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT12) External validation using real world data of a generative AI assisted medication-indication knowledge base
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT13) Patient Engagement and Adherence to Digital Tasks: WEARable Activity Tracker Study Exploring Rheumatoid Arthritis Patients’ Disease Activity using Patient-Reported Outcome Measures, Clinical Measures, and Biometric Sensor Data
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT14) Drug Burden Index is a Strong Modifiable Predictor of 30-Day Hospitalisation in Community-Dwelling Older Adults: Machine Learning Analysis of InterRAI Data.
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT15) Automation of study report abstract generation by Large Language Models, methodology and application example
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT16) Machine Learning Applications for Predicting Empirical Antibiotic Treatment Failure in Urinary Tract Infections
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT17) Trends in concomitant prescribing of anticoagulants and antiseizure medications among people with stroke in the United Kingdom.
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT18) Antidepressant long-term and potential high-risk prescribing in two Scottish health boards: a cross-sectional analysis
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT19) How many people would be eligible for treatment with nasal esketamine in Denmark? A critical assessment of the definition of treatment-resistant depression
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT20) Population-level utilization of direct-acting antiviral agents and trends in hepatitis C related hospitalizations
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT21) Global trends in outpatient gabapentinoid utilization: A cross‐sectional analysis of 67 countries
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT22) Psychotropic medication use in Australian aged care before and after aged care reforms, 2018 and 2022
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT23) Trends in Use of Antipsychotics in Germany 2014–2023: A Nationwide Population-based Study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT24) Cardiovascular Medicine Use in Adults with ADHD: A Nationwide Study in Australia
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT25) Drug-Drug Interactions Between Direct-Acting Oral Anticoagulants and Antiseizure Medications: A Target Trial Emulation
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT26) Effect of drug-drug interactions involving direct-acting oral anticoagulants and statins on the risk of bleeding
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT27) Risk of thyroid dysfunction associated with the concomitant use of amiodarone and sulfonylureas: a nationwide cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT28) The Economic Burden of Drug-Drug Interactions in an Older Population acutely admitted to Hospital in Ireland: A Propensity Score Pharmacoeconomic Analysis.
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT29) Drug-Drug Interactions in the Older Community-Dwelling Population: Findings from The Irish LongituDinal study on Ageing
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT30) The prevalent new-user design to study drug-drug interactions: the example of sulfonylureas and warfarin interaction on the risk of severe hypoglycemia
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT31) Trends in the Concurrent Use of Illicit Drugs and Interacting Prescription Medications Among Adults in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT32) Concomitant use of direct oral anticoagulants and pharmacokinetically-interacting antiarrhythmics and the risk of major bleeding in patients with non-valvular atrial fibrillation: population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT33) Antimicrobial Resistance Patterns of Escherichia coli urine isolates in the greater Sydney community from 2008 to 2018: a Geospatial Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT34) Climate vulnerability and utilization of electricity-dependent durable medical equipment among Medicare beneficiaries in North Carolina
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT35) Geographical visualization of Antibiotic use and Escherichia coli Antibiotic resistance Patterns in the greater Sydney community from 2016 to 2018
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT36) A Data-driven Approach to Unravelling the Contextual Social Determinants of Racial/Ethnic Health Disparities in Nonadherence to Antihypertensive Medications
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT37) Climate Impact of Intravenous versus Oral Antibiotics: A Comparative Waste Assessment
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT38) Endocrine disrupting chemicals associated health hazards from polyethylene terephthalates used in edible packaging: A Systematic review of clinical studies
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT39) Antimicrobial Resistance of Escherichia coli and Anti-diabetics: A Multi-year Geospatial Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT40) Evaluating the intersection of climate vulnerability and cancer burden in North Carolina
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT41) Clinical and Adverse Outcomes Associated with Concomitant Use of CYP2D6-metabolized Opioids with Antidepressants in Older Nursing Home Residents—A Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT42) Antiseizure Medications Use And the Risk Of Parkinson’s Disease: A 15-year Population-based Study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT43) Fall risk increasing adverse reactions (FRIARs) and fracture risk: A nested case control study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT44) De-Med: Developing a Tool for Identifying and Categorizing Potentially Inappropriate Medications in the Elderly Using Beers Criteria, STOPP, and FORTA - A Cross-Sectional Study
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT45) Higher dose antiviral therapy for herpes infections is associated with a risk of serious adverse events in older adults with chronic kidney disease
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT46) Comparative Effectiveness of Short Acting Opioid Escalation and Initiation of a Long-Acting Opioid in Nursing Home Residents
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT47) Utilization of Benzodiazepines in the U.S.: An Analysis of Medical Expenditure Panel Survey
Favorite
8:00 AM – 6:00 PM
CEST
(ASPOT48) Discontinuation of preventative treatments in older people with complex health needs: self-controlled case series analyses of preventable cardiovascular events
Favorite
Tuesday, August 27, 2024
8:00 AM – 6:00 PM
CEST
(001) A Novel Methodology for Assessing Response to Lymphoma Treatment using Real World Data – the Real-World Lugano (rwLugano) Study
Favorite
8:00 AM – 6:00 PM
CEST
(002) A Quantitative Bias Analysis to Assess the Impact of Tumor Selection on Linear Growth in Observational Research: a Case Study in Renal Cancer.
Favorite
8:00 AM – 6:00 PM
CEST
(003) Age and sex-specific incidence of fracture events among persons with chronic lymphocytic leukemia
Favorite
8:00 AM – 6:00 PM
CEST
(004) Antidepressant use and depressive symptoms in cancer survivors: a Danish population-based study
Favorite
8:00 AM – 6:00 PM
CEST
(005) Assessment of the potential risk of seizure among patients with prostate cancer treated with enzalutamide in China: a non-interventional study
Favorite
8:00 AM – 6:00 PM
CEST
(006) Cancer treatment and the risk of acute kidney injury
Favorite
8:00 AM – 6:00 PM
CEST
(007) Beyond external control arms: utility of real-world data in oncology regulatory applications
Favorite
8:00 AM – 6:00 PM
CEST
(008) Breast cancer incidence by subtypes - a Danish register-based study from 2012 to 2022.
Favorite
8:00 AM – 6:00 PM
CEST
(009) Breast cancer recurrence due to avoidable drug-drug interactions? Developing a protocol for a target trial in women with breast cancer who concurrently use tamoxifen and antidepressants
Favorite
8:00 AM – 6:00 PM
CEST
(010) Cardiotoxic Cancer Treatment in Screen-Detected Versus Non-Screen-Detected Breast Cancer Patients: A Study Based on German Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(011) Characteristics and treatment sequences of patients with KRAS G12C, other KRAS and KRAS-wild-type advanced or metastatic (AM) Non-Small Cell Lung Cancer (NSCLC) in the French ESME cohort
Favorite
8:00 AM – 6:00 PM
CEST
(012) Characterization of Novel Longitudinal Oncology Real World Datasets in Germany and UK
Favorite
8:00 AM – 6:00 PM
CEST
(013) Clinical Features Associated with Disease Response Classification in Lymphoma: A Comparison of Data from Manual Chart Review and Blinded Independent Central Review
Favorite
8:00 AM – 6:00 PM
CEST
(014) Current Trends in the Therapeutic Management of Metastatic Prostate Cancer in Clinical Practice
Favorite
8:00 AM – 6:00 PM
CEST
(015) Discordance between clinical and pathological stage in non-small cell lung cancer patients in China
Favorite
8:00 AM – 6:00 PM
CEST
(016) Empirical Estimation of Hepatocellular Carcinoma Prevalence in Saudi Arabia: A Gender and Age Group Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(017) Feasibility of Using Deidentified Positron Emission Tomography–Computed Tomography (PET-CT) Scans to Support a Blinded Independent Central Review for Lymphoma Treatment Response Assessment using Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(019) Incidence, Treatment Pattern, and Implications of Chemotherapy-Related Anemia in Patients with Solid Tumors in China: A Multicenter Retrospective Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(020) Incremental Burden of Comorbidity on Health-Related Quality of Life in Patients with Prostate Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(021) Ischemic Cardiotoxicity of Aromatase Inhibitors in Postmenopausal Women with Early Breast Cancer: an Analysis of Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(022) Machine Learning and Deep Learning Techniques for the Survival Prediction of Oropharyngeal Squamous Cell Carcinoma: Ahead of the Pack
Favorite
8:00 AM – 6:00 PM
CEST
(023) Neutropenia among patients with prostate cancer: Analysis of four US real world databases
Favorite
8:00 AM – 6:00 PM
CEST
(024) Performance of ChatGPT-3.5, ChatGPT-4, Microsoft Copilot, and Google Bard To Identify Correct Information for Lung Cancer
Favorite
8:00 AM – 6:00 PM
CEST
(025) Phenotype Development and Characterization of Patients with Prostate Cancer in Varying Disease Phases Using Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(026) Real-world effectiveness of oral novel hormonal agents in patients with advanced prostate cancer: a head-to-head comparison using longitudinal, territory-wide electronic medical records
Favorite
8:00 AM – 6:00 PM
CEST
(027) Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data
Favorite
8:00 AM – 6:00 PM
CEST
(028) Results from an analysis of data from the US SEER registries to estimate the prevalence of gastroenteropancreatic neuroendocrine tumors in the US, in the context of limited available evidence for regulatory discussions
Favorite
8:00 AM – 6:00 PM
CEST
(029) Risk factors for malignant transformation of oral epithelial dysplasia: a systematic review and meta-regression analysis
Favorite
8:00 AM – 6:00 PM
CEST
(030) The impact of Body Mass Index on colorectal cancer prognosis. A population-based cohort study in Denmark.
Favorite
8:00 AM – 6:00 PM
CEST
(031) The relation between tamoxifen metabolism and time to discontinuation: A Bayesian pathway analysis in premenopausal breast cancer patients
Favorite
8:00 AM – 6:00 PM
CEST
(032) Update on malignant transformation rate of oral epithelial dysplasia: a systematic review.
Favorite
8:00 AM – 6:00 PM
CEST
(033) US and Global Cutaneous Melanoma Burden: An Updated Epidemiology Assessment
Favorite
8:00 AM – 6:00 PM
CEST
(034) Vascular Endothelial Growth Factor Pathway Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection: A Nested Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(035) Assessing the utility of claims for haemoglobin A1c performance measures in characterizing glycemic control in older adult Medicare beneficiaries with diabetes.
Favorite
8:00 AM – 6:00 PM
CEST
(036) Association of educational level with clinical presentation and pharmacological treatment in 10,020 individuals with recently diagnosed type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(037) Association of multimorbidity intervals with the risk of mortality among people living with diabetes: a territory-wide nested case-control study
Favorite
8:00 AM – 6:00 PM
CEST
(038) Cardiovascular Risk of Hormone Replacement Therapy in Menopausal Women with Diabetes: A Systematic Review and Meta-Analysis of Clinical Trials and Observational Studies
Favorite
8:00 AM – 6:00 PM
CEST
(039) Comparative Analysis of Potential Misuse between Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): Insights from FDA Adverse Event Reporting System (FAERS) Data
Favorite
8:00 AM – 6:00 PM
CEST
(040) Comparative Effectiveness of Anti-TNF Therapy and Vedolizumab in Crohn's Disease Patients
Favorite
8:00 AM – 6:00 PM
CEST
(041) Comparative Protective Effect on Alzheimer Disease between GLP1-RA and SGLT2 Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(042) Comparative risk of lactic acidosis associated with initiation of metformin among patients with and without renal impairment
Favorite
8:00 AM – 6:00 PM
CEST
(043) Concomitant Use of Sulfonylurea and Amiodarone Associated with the Risk of Severe Hypoglycemia
Favorite
8:00 AM – 6:00 PM
CEST
(044) Dipeptidyl Peptidase-4 Inhibitors Use and Risk of Fracture in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Real-World Data
Favorite
8:00 AM – 6:00 PM
CEST
(045) Effect of COVID-19 restrictions on insulin consumption in Turkey: Results from Changes in Nationwide Drug Consumption During the Pandemic Study
Favorite
8:00 AM – 6:00 PM
CEST
(046) Effect of SGLT2 Inhibitors on Decreasing the Risk of Depression in Patients with Diabetes: A Nationwide Active-Comparator Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(047) Efficacy and Safety of Luseogliflozin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(048) Exploring early signals for gliptins and gliflozins: A pharmacovigilance study on recent oral antidiabetic groups in Spain.
Favorite
8:00 AM – 6:00 PM
CEST
(049) Hypoglycaemia Risk and Medication De-intensification in Diabetes Patients: A Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(050) Identifying Prediabetes Patients Using Administrative Claims Linked with Lab Data to Assess Progression To Type 2 Diabetes and Treatment Initiation Patterns
Favorite
8:00 AM – 6:00 PM
CEST
(051) Incidence of Diabetic Ketoacidosis in Dapagliflozin Users vs. SGLT2i Non-users with Type 1 Diabetes Mellitus using a Japanese Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(052) Incretin-Based Drugs and the Incidence of Endometrial Cancer Among Patients with Type 2 Diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(053) Incretin-based drugs and the risk of gallbladder or biliary tract diseases among patients with type 2 diabetes across categories of body mass index: A nationwide cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(054) Initiation of SGLT2i vs GLP1-RA and the Risk of Acute Kidney Injury in Persons with Type 2 Diabetes Mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(055) Insulin Consumption Trends in Greece: A Retrospective Analysis of Diabetes consumption based on EOPPY Dataset (2015-2020)
Favorite
8:00 AM – 6:00 PM
CEST
(056) Investigating ethnic differences in the comparative effectiveness of classes of second-line antidiabetic medications at preventing cardiovascular outcomes.
Favorite
8:00 AM – 6:00 PM
CEST
(057) Methods for Extrapolating Findings from Randomized Clinical Trials using Real-World-Data
Favorite
8:00 AM – 6:00 PM
CEST
(058) Migration Background and HbA1c Checks and Balances: A Large Routine Care Data Study in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(059) Novel Glucose-lowering Drugs and Incident Dementia Among Patients With Type 2 Diabetes and Comorbid Mental Disorders: A Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(060) Predicting Insulin Consumption in Relation to Diabetes: A Pharmacoepidemiological Analysis of the EOPYY Dataset in Greece (2015-2020)
Favorite
8:00 AM – 6:00 PM
CEST
(061) Predictive Model for Sight-Threatening Diabetic Retinopathy in People with Type 2 Diabetes Mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(062) Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary practice
Favorite
8:00 AM – 6:00 PM
CEST
(063) Psychometric properties of the Treatment Satisfaction with Medicine Questionnaire (SATMED-Q) in Indonesian patients with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(064) Real-world evidence generation methods used to estimate fracture risk with drugs to treat type 2 diabetes mellitus: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(065) Relationship between Anti-diabetic Medication Use and Glycaemic Control in an Asian Cohort with Diabetes in Singapore
Favorite
8:00 AM – 6:00 PM
CEST
(066) Risk of Acute Kidney Injury in Dapagliflozin Users with Type 2 Diabetes: A Nationwide Cohort Study with Propensity Score Matching
Favorite
8:00 AM – 6:00 PM
CEST
(067) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors in the FDA Sentinel System
Favorite
8:00 AM – 6:00 PM
CEST
(068) Risk of New-onset Type 2 Diabetes Mellitus Associated with 5-Alpha Reductase Inhibitors: A Nationwide Population-Based Study
Favorite
8:00 AM – 6:00 PM
CEST
(069) Safety of concomitant use of antidiabetic drugs and oral anticoagulants: a systematic review of observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(070) Semaglutide injection with type 2 diabetes indication – User trends and Off-label Prescribing for Weight Loss from 2018 through 2023 in Denmark
Favorite
8:00 AM – 6:00 PM
CEST
(071) Sex Disparities in Medication Changes After Metformin Initiation are Associated With Small, Clinically Non-Relevant, Sex Differences in HbA1c Levels During Follow-up
Favorite
8:00 AM – 6:00 PM
CEST
(072) Temporal Trends in the Dispensing Patterns of Semaglutide and Dulaglutide in Ireland from 2018-2023
Favorite
8:00 AM – 6:00 PM
CEST
(073) The Health Status & Related Quality of Life among Patients with T2DM using EQ-5D-5L Instrument at a Tertiary Healthcare Facility in Nigeria.
Favorite
8:00 AM – 6:00 PM
CEST
(074) The Prevalence of Depression among Patients with Type 2 Diabetes: An Umbrella Review
Favorite
8:00 AM – 6:00 PM
CEST
(075) The Use of Potentially Interacting Supplement–Drug Pairs in Adults with Type 2 Diabetes: A Large Population-Based Cohort Study in the UK Biobank
Favorite
8:00 AM – 6:00 PM
CEST
(076) Treatment Modification Patterns of Glucose-Lowering Agents in Saudi Arabia: A Retrospective Real-world Data Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(077) Trends in use of diabetes drugs in Sweden 1977–2022: A cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(078) Two-arm Study on Deprescribing of Antihyperglycemic Agents Causing Hypoglycaemia Among Geriatric Patients
Favorite
8:00 AM – 6:00 PM
CEST
(079) Use of new technologies and well-being in adults with type 1 diabetes mellitus
Favorite
8:00 AM – 6:00 PM
CEST
(080) Utilization of sodium-glucose cotransporter 2 inhibitors post-regulatory approval as an adjunctive therapy for type 1 diabetes mellitus: Insight from real-world experience in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(081) Visit-to-visit lipid variability and risk of renal outcomes among patients with type 2 diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(082) Vitamin D and the Microvascular Complications of Type 2 Diabetes in India: A Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(083) A Case-control Study On Polypharmacy And Co-medications in Alzheimer’s Disease
Favorite
8:00 AM – 6:00 PM
CEST
(084) A dynamic fall risk prediction and monitoring tool in aged care using routinely collected electronic health data: Development and internal validation of the FRIPAC tool
Favorite
8:00 AM – 6:00 PM
CEST
(085) Adherence to Hypertension Treatment Among the Older Individuals: Do Depression and Anxiety Influence Adherence Trajectories?
Favorite
8:00 AM – 6:00 PM
CEST
(086) Adverse Drug reactions in an Ageing PopulaTion rIsk Prediction Tool (ADAPtIP): the development of a model for predicting adverse drug reactions in older patients admitted to hospital
Favorite
8:00 AM – 6:00 PM
CEST
(087) Anticoagulant Deprescribing After An Emergency Department Visit Due To Gastrointestinal Bleeding Among Older Patients Using Multiple Medications
Favorite
8:00 AM – 6:00 PM
CEST
(088) Antidepressants and Risk of Orthostatic Hypotension: a Self-Controlled Case Series Study
Favorite
8:00 AM – 6:00 PM
CEST
(089) Are drugs discontinued after hospital-based medication reviews in older adults? A nationwide register-based study in 2022
Favorite
8:00 AM – 6:00 PM
CEST
(090) Association between Recently Raised Anticholinergic Burden and Risk of Delirium – A case-case-time-control Study
Favorite
8:00 AM – 6:00 PM
CEST
(091) Association between use of Furosemide and Risk of Parkinson’s disease
Favorite
8:00 AM – 6:00 PM
CEST
(092) Association of Systemic Anticholinergic Medication use and Accelerated Decrease in Lung function in Older adults.
Favorite
8:00 AM – 6:00 PM
CEST
(093) Associations between gender, race/ethnicity and age and the initiation of chronic high-risk medication in US older adults
Favorite
8:00 AM – 6:00 PM
CEST
(094) Brain Imaging In United States Veterans Before and After Establishing Criteria for Use of Anti-amyloid Therapy for Treatment of Mild Cognitive Impairment and Alzheimer’s Dementia
Favorite
8:00 AM – 6:00 PM
CEST
(095) Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort
Favorite
8:00 AM – 6:00 PM
CEST
(096) Comparing Dementia and Cognitive Impairment Risks in Older Type-2 Diabetic Patients: A Danish Register-Based Study on Dipeptidyl Peptidase-4 Inhibitors vs. Glucagon-like Peptide-1 Analogues
Favorite
8:00 AM – 6:00 PM
CEST
(097) Cost-Effectiveness of Lecanemab (Leqembi) for Individuals With Early-Stage Alzheimer’s Disease
Favorite
8:00 AM – 6:00 PM
CEST
(098) Dementia Medications and their Association with Pain Medication Use in Medicare Beneficiaries with Dementia and Chronic Pain
Favorite
8:00 AM – 6:00 PM
CEST
(099) Description of time trends in the of users of Janus kinase inhibitors in Sweden using a joinpoint regression approach
Favorite
8:00 AM – 6:00 PM
CEST
(100) Developing a novel claim-based algorithm to identify incident and prevalent dementia using Medicare claims of the Atherosclerosis Risk in Communities (ARIC) cohort
Favorite
8:00 AM – 6:00 PM
CEST
(101) Discontinuation of chronically used medication in routine clinical practice among Swedish older adults: A nationwide cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(102) Drug target Mendelian Randomisation vs regression methods: estimating causal effects of sclerostin inhibition on bone mineral density and fracture risk
Favorite
8:00 AM – 6:00 PM
CEST
(103) Effectiveness and Safety of Oral Anticoagulants among Long-term Nursing Home Residents with atrial fibrillation (AF) and Moderate to Severe Impairment in Functional Status
Favorite
8:00 AM – 6:00 PM
CEST
(104) Effectiveness of Gabapentinoids versus Muscle Relaxants on Opioid Discontinuation among Older Adults with Prolonged Opioid Use
Favorite
8:00 AM – 6:00 PM
CEST
(105) Effectiveness of Mono and Dual Antidementia Pharmacotherapy Among US Nursing Home Residents
Favorite
8:00 AM – 6:00 PM
CEST
(106) Epidemiological Landscape of Human Metapneumovirus Among Older Adults in High-Income Countries: Systematic Literature Review and Meta-Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(107) Estimating the Prevalence of Preclinical Alzheimer’s Disease with Subjective Cognitive Decline among US Adults
Favorite
8:00 AM – 6:00 PM
CEST
(108) Evaluating Caregiver Quality of Life, Indirect and Intangible Costs and their Association with Alzheimer’s Disease Severity in the US
Favorite
8:00 AM – 6:00 PM
CEST
(109) Evaluating Drug Use Patterns in Hospitalized Elderly: A Study on Polypharmacy and Compliance
Favorite
8:00 AM – 6:00 PM
CEST
(110) Evaluating Lecanemab Eligibility for Patients in Skilled Nursing Facilities with Alzheimer's Disease or Mild Cognitive Impairment
Favorite
8:00 AM – 6:00 PM
CEST
(111) Evaluation of QT Prolonging Drug Use Among Elderly with Psychiatric Disorders in India using Beers Criteria(2019) and STOPP Criteria(2015)
Favorite
8:00 AM – 6:00 PM
CEST
(112) Exploring Anticholinergic Co-Medication Networks in HIV and Frailty: An Exploratory Random Graph Modelling Approach
Favorite
8:00 AM – 6:00 PM
CEST
(113) Exploring the Association Between Intention and Action in Deprescribing
Favorite
8:00 AM – 6:00 PM
CEST
(114) Exploring the Feasibility and added Value of a Comorbidity Index Score in a Pharmacovigilance Database
Favorite
8:00 AM – 6:00 PM
CEST
(115) Factors associated with potentially inappropriate medicines use in older adults during the covid-19 pandemic in two Brazilian municipalities: a cross-sectional study
Favorite
8:00 AM – 6:00 PM
CEST
(116) Feasibility of a Federated Network Analysis Using Real-World Data Mapped to OMOP Common Data Model to Estimate Healthcare Resource Utilisation and Costs of Imminent Subsequent Fracture
Favorite
8:00 AM – 6:00 PM
CEST
(117) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson’s Disease in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(118) Glucagon-Like Peptide-1 Receptor Agonists and Risk of Suicide/Self-harm in U.S. Older Adults with Type 2 Diabetes: A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(119) Glucose lowering medication utilization before and after entry into long-term care among older people with diabetes
Favorite
8:00 AM – 6:00 PM
CEST
(120) How much frequently are biological drugs used in patients over 65 years with immune-mediated inflammatory diseases through the Italian VALORE distributed database network
Favorite
8:00 AM – 6:00 PM
CEST
(121) Identifying Clustering of Clinic-level Prescribing Patterns for Patients with Differing Health Coverage in Primary Care in Ireland: a Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(122) Implementation of a cluster-based High-Performance Computing solution for logistic regression, random forest and XGBoost algorithms to predict memory impairment in older adults
Favorite
8:00 AM – 6:00 PM
CEST
(123) Improving Prescription Appropriateness of Proton Pump Inhibitors: The LAPTOP-PPI Study
Favorite
8:00 AM – 6:00 PM
CEST
(124) Incidence and Complications of Rectopexy in the United Kingdom and United States, 2013-2022.
Favorite
8:00 AM – 6:00 PM
CEST
(125) Low-Dose Aspirin and Risk of Anemia in Older Adults: Insights from a Danish Register-based Study
Favorite
8:00 AM – 6:00 PM
CEST
(126) Medicare Annual Wellness Visits and Incident Alzheimer’s Disease Diagnosis among a Medicare Advantage Population, 2016-2022
Favorite
8:00 AM – 6:00 PM
CEST
(127) National trends in utilization of glucose lowering medications by older people with diabetes in long-term care facilities, 2009 to 2019
Favorite
8:00 AM – 6:00 PM
CEST
(128) Network Analysis of Chronic Medication Use in Older Adults Living with Dementia Prior to and Following Diagnosis: A Web-based Visualisation Tool
Favorite
8:00 AM – 6:00 PM
CEST
(129) Older US adults refilling potentially inappropriate medications after hip fracture
Favorite
8:00 AM – 6:00 PM
CEST
(130) PARTNER pilot study: Interprofessional clinical pathway to patient-oriented deprescribing of psychotropic and anticholinergic medications in elderly patients with polypharmacy
Favorite
8:00 AM – 6:00 PM
CEST
(131) Pharmacological treatments and medication-related problems in nursing homes in Catalonia: The impact of a multidisciplinary team intervention
Favorite
8:00 AM – 6:00 PM
CEST
(132) Polypharmacy and Potentially Inadequate Medication in Older Adults: Results from the German National Cohort (NAKO) Baseline.
Favorite
8:00 AM – 6:00 PM
CEST
(133) Prescription Sequence Symmetry Analysis to Identify Prescription Cascades for Dementia Drug Treatments in the United Kingdom
Favorite
8:00 AM – 6:00 PM
CEST
(134) Prevalence and factors associated with polypharmacy and self-medication among the elderly population residing in urban Indian communities
Favorite
8:00 AM – 6:00 PM
CEST
(135) Primary Care Resource Utilisation and Costs of Fragility Fractures in Postmenopausal Women in the UK Using CPRD Data Mapped to OMOP Common Data Model
Favorite
8:00 AM – 6:00 PM
CEST
(136) Regional Variations Between Drug Treatment Recommendations for Insomnia in Older People in Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(137) Risk of sarcopenia following long-term statin use in community-dwelling middle-aged and older adults in Japan: evidence from a 10-year population-based cohort study using propensity score matching and overlap weighting
Favorite
8:00 AM – 6:00 PM
CEST
(138) Risk of ventricular arrhythmias or sudden cardiac death and acetylcholinesterase inhibitors among older adults with dementia
Favorite
8:00 AM – 6:00 PM
CEST
(139) Risk Prediction Models for Adverse Drug Reactions and Adverse Drug Events in Older Adults – A Systematic Review
Favorite
8:00 AM – 6:00 PM
CEST
(140) SGLT2 inhibitors and Parkinson’s disease (PD) risk in older populations with type 2 diabetes (T2D)
Favorite
8:00 AM – 6:00 PM
CEST
(141) Spousal bereavement and four-year trajectories of medication use: a nationwide register-based study in Swedish older adults
Favorite
8:00 AM – 6:00 PM
CEST
(142) Telehealth's Impact in Alzheimer's Medication Management: A Real-World EMR Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(143) The prevalent new-user study design: a novel application to estimating the average treatment effect of statin discontinuation on mortality among traditional Medicare beneficiaries who discontinued statins
Favorite
8:00 AM – 6:00 PM
CEST
(144) Trends of the prevalence of polypharmacy and potentially inappropriate medications in people with dementia from 2006 to 2021 in Hong Kong
Favorite
8:00 AM – 6:00 PM
CEST
(145) Unraveling the use of diagnostic tests for mild cognitive impairment, Alzheimer’s disease, and other dementias: a real-world study
Favorite
8:00 AM – 6:00 PM
CEST
(146) Use of Immunomodulators/Biologics is protective against Major Adverse Cardiovascular Events in Medicare patients with Inflammatory Bowel Disease over use of 5-ASA alone.
Favorite
8:00 AM – 6:00 PM
CEST
(147) Which Medication Counting Method is Useful for Predicting Death and Institutionalization in Older Adults? A Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(148) Assessing Data Discontinuity: A Study of Atrial Fibrillation Recurrence Across Hospital Boundaries Using Tokenization
Favorite
8:00 AM – 6:00 PM
CEST
(149) Association of Global Evaluative Assessment of Robotic Skills (GEARS) Scores with Operative Time for Robotic Hysterectomy: a Retrospective Study
Favorite
8:00 AM – 6:00 PM
CEST
(150) Characterizing device and treatment of patients with deep dermal or full thickness thermal burns in the National Burn Registry between 2021-2023
Favorite
8:00 AM – 6:00 PM
CEST
(151) Clinical and Economic Outcomes of Cesarean Deliveries with Skin Closure through Conventional Sutures Plus Waterproof Wound Dressings versus 2-octyl Cyanoacrylate Plus Polymer Mesh Tape
Favorite
8:00 AM – 6:00 PM
CEST
(152) Determinants of Use of Minimally Invasive Robot-Assisted Surgery: a Cohort Study from the French Nationwide Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(153) Evaluation of the Adverse Effects of Family Planning Implants in Nigerian Women in Lagos State
Favorite
8:00 AM – 6:00 PM
CEST
(155) How much data are lost in longitudinal studies of medical devices using hospital databases? Hospital data linked with claims data for Atrial Fibrillation ablation treatment.
Favorite
8:00 AM – 6:00 PM
CEST
(156) How well does hospital billing data estimate readmissions and revision risks after spinal fusion surgery compared to hospital billing linked to claims data?
Favorite
8:00 AM – 6:00 PM
CEST
(157) Postoperative Clinical and Economic Outcomes of Patients with Reverse or Anatomic Total Shoulder Arthroplasty at One Year: A Retrospective, United States Hospital Billing Database Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(158) Predictors Of The Utilization Of Lung Cancer Screening With Low-Dose Computed Tomography (LDCT) In The United States (US) Commercially Insured Population
Favorite
8:00 AM – 6:00 PM
CEST
(159) Readmission Rates and Costs Associated with the Use of Enterprise 2 and Neuroform Atlas Stents for Unruptured Intracranial Aneurysms: A Comparative Real-World Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(160) Real-world data collection for medical device regulatory submissions: Considerations in epidemiology
Favorite
8:00 AM – 6:00 PM
CEST
(161) Risk of Thermal Burns in Electrosurgery: A U.S. cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(162) Switching and continuation patterns of consecutive IUD users - results from a large observational, real-world study in Europe (EURAS-LCS12)
Favorite
8:00 AM – 6:00 PM
CEST
(163) Trends in Adoption of Knotless Tissue Control Devices in Robotic Surgery: A Retrospective Database Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(164) Use of Real-World Data to Evaluate Overall Survival Following Robotic-Assisted Versus Non-Robotic Assisted Radical Prostatectomy
Favorite
8:00 AM – 6:00 PM
CEST
(165) A hypothetical case study describing different intercurrent events in an observational prospective study: Differential interpretation of results
Favorite
8:00 AM – 6:00 PM
CEST
(166) A Novel, Hypothesis-free Approach to Detecting Safety Signals by Clustering Distributed Representations of Adverse Events Based on Claims Databases
Favorite
8:00 AM – 6:00 PM
CEST
(167) A retrospective look at the efficiency of 100% source data verification and the possibilities presented by risk-based quality management in increasing monitoring efficiency while maintaining good data quality.
Favorite
8:00 AM – 6:00 PM
CEST
(168) A step-by-step guide for incorporating estimands in observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(169) Application of the Target Trial Emulation Framework to External Comparator Studies
Favorite
8:00 AM – 6:00 PM
CEST
(170) Minimizing Confounding in Comparative Observational Studies with Time-To-Event Outcomes: An Extensive Comparison of Covariate Balancing Methods Using Monte Carlo Simulation
Favorite
8:00 AM – 6:00 PM
CEST
(171) Assessing the potential for sequential channeling bias for drugs with continuously expanded patient populations: an illustrative example using dupilumab
Favorite
8:00 AM – 6:00 PM
CEST
(172) Assessing the Use of the Estimand Framework in Recent Pharmacoepidemiologic Post-market Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(173) Characterization of treatment and disease burden of patients with bipolar disorder using Observational Medical Outcomes Partnership (OMOP) mapped datasets
Favorite
8:00 AM – 6:00 PM
CEST
(174) Comparing publicly available methods for assessing covariate balance using standardized differences after implementation of weighting strategies
Favorite
8:00 AM – 6:00 PM
CEST
(177) Development and Clinical Validation of a Generative AI Assisted Medication-Indication Knowledge Base
Favorite
8:00 AM – 6:00 PM
CEST
(178) Enhancing Data Continuity: Tokenized Linkage Extends Patient Observations for Real World Evidence Generation - A Komodo Research Dataset Study
Favorite
8:00 AM – 6:00 PM
CEST
(179) Excluding or Censoring on Mediators and the Resulting Causal Estimands: An Example of Hormonal Contraceptives and Venous Thromboembolism Risk
Favorite
8:00 AM – 6:00 PM
CEST
(180) External Comparator Cohort studies – clarification of terminology
Favorite
8:00 AM – 6:00 PM
CEST
(181) External Comparators and Estimands
Favorite
8:00 AM – 6:00 PM
CEST
(182) Factors associated with Remote Recruiting in Patient Centered Outcomes Research Studies
Favorite
8:00 AM – 6:00 PM
CEST
(183) Feasibility of Constructing an External Control Arm with Real-World Data to Augment Subgroups in Cardiorenal Trials: A Matched Cohort Study Focusing on Trial Subgroups of Sodium-Glucose Cotransport 2 Inhibitor Users at Baseline
Favorite
8:00 AM – 6:00 PM
CEST
(184) Feasibility of the OMOP Common Data Model for German claims data
Favorite
8:00 AM – 6:00 PM
CEST
(185) Federated learning as a smart tool for data analysis in infectious disease research: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(186) Flexible parametric survival models for simultaneous estimation on multiple timescales: an application using nationwide Swedish register data
Favorite
8:00 AM – 6:00 PM
CEST
(187) Identifying the average treatment effect in the treated: Illustration using the Northwest Germany Stroke Registry.
Favorite
8:00 AM – 6:00 PM
CEST
(188) Improved Prediction of Overall Survival Using Machine Learning Survival Models Incorporating Time-Dependent Features
Favorite
8:00 AM – 6:00 PM
CEST
(189) Improving the Role of External Control Arms in Early-Phase Single Arm Trials
Favorite
8:00 AM – 6:00 PM
CEST
(190) Investigation of inclusion and exclusion criteria in Alzheimer’s disease clinical trials on patient sample representation through natural language processing
Favorite
8:00 AM – 6:00 PM
CEST
(191) Landscape Assessment of Clone-Censor-Weight Methodology Application in Real-World Data Studies: A Scoping Review
Favorite
8:00 AM – 6:00 PM
CEST
(192) Line of therapy algorithm for real-world data analysis in multiple myeloma
Favorite
8:00 AM – 6:00 PM
CEST
(193) Medication Data in Research: Improving Completeness Using Rule-based Algorithms on Textual Variables
Favorite
8:00 AM – 6:00 PM
CEST
(194) Ontology-based Semantic Similarity Measures in Drug Safety: A Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(195) Optimal matching ratios for the analysis of time-to-event outcomes in matched cohort studies in EHR research: A simulation study
Favorite
8:00 AM – 6:00 PM
CEST
(196) PRE2DUP-R, open source program for assessment of PREscriptions to Drug Use Periods
Favorite
8:00 AM – 6:00 PM
CEST
(197) Predicting CRC Screening Uptake using Machine Learning and Ensemble Models
Favorite
8:00 AM – 6:00 PM
CEST
(198) Predicting survival using geriatric assessment (GA) in older adults with advanced cancer using least absolute selection and shrinkage operator (LASSO)
Favorite
8:00 AM – 6:00 PM
CEST
(199) Proof-of-concept for a UK federated data network using the OMOP common data model: the UK regulatory studyathon
Favorite
8:00 AM – 6:00 PM
CEST
(200) Scalable Natural Language Processing for Large-Scale Covariate Adjustment in Healthcare Database Studies
Favorite
8:00 AM – 6:00 PM
CEST
(201) Specifying the target trial reveals exceptions to commonly accepted rules of target trial emulation
Favorite
8:00 AM – 6:00 PM
CEST
(202) Systematic Definition Development of Variables of Interest for Studies Using Administrative Databases
Favorite
8:00 AM – 6:00 PM
CEST
(203) Testing machine learning prediction models to impute missing data in claims databases
Favorite
8:00 AM – 6:00 PM
CEST
(204) The Current Use of Single Arm Trials (SAT): A Targeted Literature Review
Favorite
8:00 AM – 6:00 PM
CEST
(205) There's something about Albumin: Applying the Roadmap for Causal Inference to Estimate the Effect of Albumin Levels on Pressure Injury Development in Hospital Settings
Favorite
8:00 AM – 6:00 PM
CEST
(206) Trials Replication through Observational study across OHDSI (TROY)
Favorite
8:00 AM – 6:00 PM
CEST
(207) Understanding the Utility of Historical Cohort Studies Via Retrospective Chart Review in Inflammatory Bowel Disease: A Review of Global Studies
Favorite
8:00 AM – 6:00 PM
CEST
(208) Using large language models with real world data to support regulatory decision-making for medicinal products: Are we on the road to regulatory convergence or chaos?
Favorite
8:00 AM – 6:00 PM
CEST
(209) What Exactly Does Clone-Censor-Weighting Estimate When Studying Treatment Initiation Windows, Anyway?
Favorite
8:00 AM – 6:00 PM
CEST
(210) Adjunctive treatments for depression: Delineating real-world treatment patterns
Favorite
8:00 AM – 6:00 PM
CEST
(211) Agomelatine and Inverse Risk of Hypertension, Diabetes and Hyperlipidemia: A Nationwide Active-comparator Study
Favorite
8:00 AM – 6:00 PM
CEST
(212) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of methylphenidate and potential signal for obsessive-compulsive disorders
Favorite
8:00 AM – 6:00 PM
CEST
(213) An Assessment of Use and Emerging Safety of Esketamine Nasal Spray in the U.S., 2019-2023
Favorite
8:00 AM – 6:00 PM
CEST
(214) Characteristics and drug utilization patterns of patients with migraine initiating erenumab in Nordic countries
Favorite
8:00 AM – 6:00 PM
CEST
(215) Concurrent Use of Prescription Benzodiazepines and Cannabis in Prevalent Medical Cannabis Users with Mental Health Conditions: A Cross-Sectional Survey
Favorite
8:00 AM – 6:00 PM
CEST
(216) Deprescribing of antidepressants: Development of indicators of high-risk and overprescribing using the RAND/UCLA Appropriateness Method
Favorite
8:00 AM – 6:00 PM
CEST
(217) Effectiveness of low-dose amitriptyline and mirtazapine in insomnia disorder: a randomised, double-blind, placebo-controlled trial in general practice (the DREAMING study)
Favorite
8:00 AM – 6:00 PM
CEST
(218) Estimation of Daily Delta-9-Tetrahydrocannabinol Doses Among Participants in Florida's Medical Marijuana Use Registry: A Study on Trends and Patterns in Medical Cannabis Utilization
Favorite
8:00 AM – 6:00 PM
CEST
(219) Identification of migraine in electronic healthcare data sources: a headache for pharmacoepidemiologists – a systematic literature review
Favorite
8:00 AM – 6:00 PM
CEST
(220) Impact of deregulation of the Brazilian National Controlled Products Management System on antidepressants’ sales data
Favorite
8:00 AM – 6:00 PM
CEST
(221) Incidence of moderate and profound hyponatremia during treatment with selective serotonin reuptake inhibitors (SSRIs) – evidence from the Stockholm Sodium Cohort (SSC).
Favorite
8:00 AM – 6:00 PM
CEST
(222) Medically-attended cannabis-related disorders among U.S. Medicare beneficiaries, 2017–2022
Favorite
8:00 AM – 6:00 PM
CEST
(223) Modeling Medical, Prescription, Disability, and Absence Costs for Employees with Major Depressive Disorder (MDD): Using Shorter Pre-Index Time Periods for Charlson Comorbidity Indexes (CCI) and Smaller Sample Sizes
Favorite
8:00 AM – 6:00 PM
CEST
(224) Patient characteristics associated with new community prescription of benzodiazepine and z-drug hypnotics after critical illness in the UK, a retrospective cohort study.
Favorite
8:00 AM – 6:00 PM
CEST
(225) Peyronie´s disease and risk of depression. A nationwide 25-year cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(226) Prevalence and sociodemographic characteristics of people with prescription stimulant use disorder: results from the National Survey on Drug Use and Health, 2015-2019
Favorite
8:00 AM – 6:00 PM
CEST
(227) Risk assessment of decreased platelet count in patients prescribed antidepressants using the MID-NET in Japan
Favorite
8:00 AM – 6:00 PM
CEST
(228) Trends of Triptans Use in Hungary
Favorite
8:00 AM – 6:00 PM
CEST
(229) A national population cohort study of congenital abnormalities following SARS-CoV-2 infection and COVID-19 vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(230) A Population-Based Cohort Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP): Rationale, Design, and Baseline Characteristics
Favorite
8:00 AM – 6:00 PM
CEST
(231) A Target Trial of Pre-conception Switch from a Legacy Medication to a New Medication – An Application to Antiretroviral Therapy and Birth Outcomes
Favorite
8:00 AM – 6:00 PM
CEST
(232) Addressing Over-Representation of Early Pregnancy Outcomes in Database Pregnancy Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(233) Algorithms to identify major congenital malformations in routinely collected healthcare databases: A systematic literature review
Favorite
8:00 AM – 6:00 PM
CEST
(234) Analysis of Medicinal Product Utilization Data in the FDA Sentinel System to Inform the Development of a Pregnancy Safety Study Framework
Favorite
8:00 AM – 6:00 PM
CEST
(235) Analysis of Postapproval Pregnancy Safety Studies Associated with FDA Approved Products
Favorite
8:00 AM – 6:00 PM
CEST
(236) Apgar-5 scores variability and associated pregnancy outcomes among hospitalized women: Insights from national linked Brazilian secondary databases
Favorite
8:00 AM – 6:00 PM
CEST
(237) Application of a direct-to-participant EMR data collection platform for pregnancy registries
Favorite
8:00 AM – 6:00 PM
CEST
(238) Assessing the Credibility of Causal Effects: A Critical Analysis of Observational Studies on Pregnancy Drug Use and Congenital Malformations
Favorite
8:00 AM – 6:00 PM
CEST
(239) Association Between Levothyroxine Supplementation for Hypothyroidism in Late Pregnancy and Risk of Preterm Delivery
Favorite
8:00 AM – 6:00 PM
CEST
(240) Association Between Maternal Anticholinergic Burden During Pregnancy and the Risk of Autism Spectrum Disorder: A Population-Based Cohort Study in Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(241) Association of First Trimester Macrolide Use With Congenital Malformations in the Offspring
Favorite
8:00 AM – 6:00 PM
CEST
(242) Association of prenatal antiseizure medication exposure with risk of neurodevelopmental disorders in children
Favorite
8:00 AM – 6:00 PM
CEST
(243) Associations Between Chronic Diseases and Treatments During Lactation and Maternal Mental Health
Favorite
8:00 AM – 6:00 PM
CEST
(244) Associations between diphenhydramine and specific birth defects stratified by imputed indication, National Birth Defects Prevention Study and Birth Defects Study to Evaluate Pregnancy exposureS
Favorite
8:00 AM – 6:00 PM
CEST
(245) Benefit-Risk Assessment of Herbal Medicines Used During Pregnancy and Lactation: A Descriptive Study of Registered Herbal Medicines in Bulgaria
Favorite
8:00 AM – 6:00 PM
CEST
(246) Changes in the Use of Carbamazepine Before, During and After Pregnancy: A Nationwide Study in France between 2013 and 2021
Favorite
8:00 AM – 6:00 PM
CEST
(247) Characterization of Pregnancy in Women of Childbearing Potential with ASCVD or Likely Familial Hypercholesterolemia: US Claims Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(248) Cohort event monitoring of COVID-19 vaccine safety using patient-reported outcomes in pregnant women.
Favorite
8:00 AM – 6:00 PM
CEST
(249) Comparator Cohort Selection: a Review of Prospective Pregnancy Registries for Multiple Sclerosis (MS) Products
Favorite
8:00 AM – 6:00 PM
CEST
(250) Comparison of Diagnoses Code Profile and Major Congenital Malformation (MCM) Prevalence across US and EU MCM Classification Systems
Favorite
8:00 AM – 6:00 PM
CEST
(251) Comprehensive evaluation of algorithm demonstrates robust performance identifying pregnancy cases in VigiBase
Favorite
8:00 AM – 6:00 PM
CEST
(252) Covid19 Vaccination During Pregnancy: a Descriptive Study of Uptake and Safety for Mothers and Infants Using the Nationwide French National Health System
Favorite
8:00 AM – 6:00 PM
CEST
(253) COVID-19 vaccination rate among pregnant women in France: a nationwide study
Favorite
8:00 AM – 6:00 PM
CEST
(254) Development of a Pregnancy Cohort in Commercial Insurance Claims Data: Evaluation of Inpatient Versus Apparent Outpatient Deliveries
Favorite
8:00 AM – 6:00 PM
CEST
(255) Disparities in asthma severity and treatment during pregnancy: description of the Slone Birth Defects Study data
Favorite
8:00 AM – 6:00 PM
CEST
(256) Effect of Tumor Necrosis Factor Inhibitor Use During Pregnancy on Gestational Diabetes Mellitus Among Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(257) Effectiveness of Awareness/Recruitment Activities for Pregnancy Registries
Favorite
8:00 AM – 6:00 PM
CEST
(258) Enhanced pharmacovigilance reporting using PRIM: conditions to make it an alternative to traditional pregnancy registry
Favorite
8:00 AM – 6:00 PM
CEST
(259) Evaluating the Incidence and Burden of Gestational Diabetes in the United States: A Retrospective Study (2015-2022)
Favorite
8:00 AM – 6:00 PM
CEST
(260) Evaluation of Digital Data collection Methods in a Prospective Pregnancy Registry for a Migraine Product with Both Acute and Preventive Indications
Favorite
8:00 AM – 6:00 PM
CEST
(261) Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study with sibling matched analysis
Favorite
8:00 AM – 6:00 PM
CEST
(262) Exposure to potentially harmful drugs during pregnancy in women with rheumatoid arthritis – a German claims data analysis
Favorite
8:00 AM – 6:00 PM
CEST
(264) Fetal and Neonatal Alloimmune Thrombocytopenia: Systematic Literature Review and Challenges Encountered
Favorite
8:00 AM – 6:00 PM
CEST
(265) Finding the Forest in the TreeScan: A Big Data Driven Approach to Screening Drug Use in Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(266) First trimester tetracycline use and risk of major congenital malformations: A cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(267) Frequency of diagnosis codes for infant outcomes appearing on maternal health insurance claims
Favorite
8:00 AM – 6:00 PM
CEST
(268) Human Breastmilk Microbiome in Individuals with Hypothyroidism Treated with Levothyroxine Compared to Healthy Controls
Favorite
8:00 AM – 6:00 PM
CEST
(269) Identification of Maternal Characteristics, Pregnancy Characteristics and Pregnancy Outcomes through Linked Maternal and Infant Databases in Brazil
Favorite
8:00 AM – 6:00 PM
CEST
(270) Impacts of Dobbs Decision and COVID-19 on Abortion-related Trends within TriNetX Electronic Medical Record Data
Favorite
8:00 AM – 6:00 PM
CEST
(271) Improving Access to HIV-Related Healthcare, including Treatment and Pre-Exposure Prophylaxis (PrEP) in Zimbabwe Among Young Mothers Living with HIV
Favorite
8:00 AM – 6:00 PM
CEST
(272) Incidence of pregnancy among publicly and commercially insured childbearing-age women with warfarin treatment
Favorite
8:00 AM – 6:00 PM
CEST
(273) Is Hypothyroidism in Pregnancy Overtreated? A Retrospective Cohort Study from Bulgaria
Favorite
8:00 AM – 6:00 PM
CEST
(274) Language and racial disparities in initial COVID-19 vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(275) Linkage of Mother and Infant Records using Commercial Claims Data within the Food and Drug Administration (FDA) Biologics Effectiveness and Safety (BEST) Initiative
Favorite
8:00 AM – 6:00 PM
CEST
(276) Linkage of Pregnancies and Infants to Potential Male Parents in a Health Insurance Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(277) Lower Rates of Initiation of Breastfeeding and Exclusive breastfeeding in Women Treated with Chronically Used Anti-inflammatory Medications
Favorite
8:00 AM – 6:00 PM
CEST
(278) Maternal and Infant Outcomes Following Infliximab Exposure During Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(279) Maternal outcomes in women receiving COVID-19 vaccination during pregnancy compared with influenza vaccines in spontaneous reporting databases
Favorite
8:00 AM – 6:00 PM
CEST
(280) Miscarriage Preventing Herbal Medicines and the Risk of Birth Defects: A Population-Based Cohort Study of 195,824 Pregnancies
Favorite
8:00 AM – 6:00 PM
CEST
(281) Neonatal Intensive Care Unit Services among Commercially Insured Infants in the United States, 2016 – 2023
Favorite
8:00 AM – 6:00 PM
CEST
(282) Opioid Analgesic and Antidepressant Use During Pregnancy and the Risk of Spontaneous Preterm Birth: A Nested Case-Control Study
Favorite
8:00 AM – 6:00 PM
CEST
(283) Opioid Toxicity in the Year After Pregnancy Among Women with Disabilities
Favorite
8:00 AM – 6:00 PM
CEST
(284) Oral Antihypertensives in Hypertensive Pregnancy and the Association with Fetal Growth: a Population-Based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(285) Outcome-Anchored Cohorts to Prevent Pregnancy Study Pitfalls: A Conceptual Approach for Preventing Bias in Post-Approval Pregnancy Safety Studies
Favorite
8:00 AM – 6:00 PM
CEST
(287) Paternal exposure to valproate and the risk of Neuro-Developmental Disorders in offspring: a population-based cohort study in Denmark, Norway and Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(288) Patterns of Prescribed and Dispensed Medicines among Non-Hospitalized Pregnant women with COVID-19: a Prospective Meta-analysis pooling findings from Healthcare Databases in Europe and North America
Favorite
8:00 AM – 6:00 PM
CEST
(289) Patterns of prescribing antihypertensive medications during pregnancy in the UK
Favorite
8:00 AM – 6:00 PM
CEST
(290) Periconceptional Oral Contraceptive Use and the Risk of Spontaneous Abortion: Results From the PRIDE Study.
Favorite
8:00 AM – 6:00 PM
CEST
(291) Postpartum Treatment Initiation among Pregnancies Diagnosed with Hepatitis C between 2016-2021 using the United States Commercial Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(292) Prediction of Hemolytic Disease of the Fetus and Newborn in neonates from alloimmunized pregnancies
Favorite
8:00 AM – 6:00 PM
CEST
(293) Predictors for correct vitamin D intake among pregnant women in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(294) Pregnancies and prescription drug use during pregnancy in women of childbearing potential with chronic spontaneous urticaria in the United States – A descriptive analysis
Favorite
8:00 AM – 6:00 PM
CEST
(295) Pregnancies with Unknown Outcome in CPRD Aurum: Investigation Conducted as Part of the Feasibility Assessment for a Potential Non-Interventional Post-Authorization Safety Study.
Favorite
8:00 AM – 6:00 PM
CEST
(296) Pregnancy and infant outcomes in gestationally-diagnosed breast cancer: A pilot study in Finland and Norway from the IMI ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(297) Pregnancy and Pain Outcomes When Elagolix and Hormonal Contraceptives are Used Concomitantly: A Prospective Cohort Study Using a Health Insurance Claims Database
Favorite
8:00 AM – 6:00 PM
CEST
(298) Pregnancy Outcomes and Maternal Morbidity Using Administrative Claims Data in the US
Favorite
8:00 AM – 6:00 PM
CEST
(299) Pregnant persons' perceptions of RSV vaccination during pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(300) Prenatal exposure to antiseizure medications and neurodevelopmental disorders: Children population-based cohort from the Quebec Pregnancy/Child Cohort
Favorite
8:00 AM – 6:00 PM
CEST
(301) Prenatal Exposure to Gabapentin and the Risk of Autism Spectrum Disorder in Children
Favorite
8:00 AM – 6:00 PM
CEST
(302) Prenatal syphilis in the US: characterizing screening and treatment during pregnancy in publicly and commercially insured individuals
Favorite
8:00 AM – 6:00 PM
CEST
(303) Prevalence of major congenital malformations in France between 2010 and 2021: estimates among the 9 millions children and foetuses of the EPI-MERES register and relevance for perinatal pharmacoepidemiology
Favorite
8:00 AM – 6:00 PM
CEST
(304) Prevalence of medication use for COVID-19 treatment in pregnancy: a two-stage individual patient data meta-analysis combining international registries.
Favorite
8:00 AM – 6:00 PM
CEST
(305) Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework
Favorite
8:00 AM – 6:00 PM
CEST
(306) Recreational drug use in Pregnancy: An observational study
Favorite
8:00 AM – 6:00 PM
CEST
(307) Replicating a Published Real-World Evidence Study to Analyze Maternal Delivery Complications Using Electronic Medical Records from Community Hospitals
Favorite
8:00 AM – 6:00 PM
CEST
(308) Reproductive safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) after maternal exposure in early pregnancy: a comparative ENTIS cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(309) Retrospective Application of the FDA Preliminary Pregnancy Safety Studies Framework to an Ongoing Pregnancy-Related Commitment
Favorite
8:00 AM – 6:00 PM
CEST
(310) Risk of congenital ocular anomaly in EUROmediCAT: Assessment of the Potential Risk of Taking Medications during Pregnancy in Europe.
Favorite
8:00 AM – 6:00 PM
CEST
(311) Risk of Neonatal and Maternal Adverse Events of Oral Anti-hypertensive Medications Used in Pregnancy: Evidence Synthesis from a Disproportionality Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(312) Sources and Characteristics of Quantitative Human Pregnancy Safety Data in U.S. FDA Approved Product Labeling, 2015-2021
Favorite
8:00 AM – 6:00 PM
CEST
(313) Specific congenital anomalies associated with maternal Multiple Sclerosis: A ConcePTION European case-malformed control study
Favorite
8:00 AM – 6:00 PM
CEST
(314) The association between COVID-19 vaccination during pregnancy and neonatal health outcomes
Favorite
8:00 AM – 6:00 PM
CEST
(315) The BELpREG Registry on Perinatal Medication Exposure and Mother-Infant Outcomes: Preliminary Insights into this unique Pregnancy Cohort in Belgium
Favorite
8:00 AM – 6:00 PM
CEST
(316) The IMEDS Distributed Database Network and Pregnancy Studies
Favorite
8:00 AM – 6:00 PM
CEST
(317) The Impact of the Mother-Infant Linkage Process in US Health Insurance Claims Data on the Representativeness of the Infant Sample
Favorite
8:00 AM – 6:00 PM
CEST
(318) The occurrence of specific congenital anomalies associated with maternal Systemic Lupus Erythematosus: A ConcePTION Case-malformed control study in EUROmediCAT
Favorite
8:00 AM – 6:00 PM
CEST
(319) The PregVal Project. A Population-based Cohort to Assess Drug Use and Safety During Pregnancy.
Favorite
8:00 AM – 6:00 PM
CEST
(320) The Risk of Postpartum Depression Based on Attention-Deficit/Hyperactivity Disorder Medication Use During Pregnancy
Favorite
8:00 AM – 6:00 PM
CEST
(321) Uptake of prescription smoking cessation pharmacotherapies during pregnancy: a population-based utilisation study across Australia, New Zealand, Norway, and Sweden
Favorite
8:00 AM – 6:00 PM
CEST
(322) US Claims Adaptation of the European Concerted Action on Congenital Anomalies and Twins (EUROCAT) Guide 1.5 for Use in Pregnancy Studies
Favorite
8:00 AM – 6:00 PM
CEST
(323) Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: a scoping review
Favorite
8:00 AM – 6:00 PM
CEST
(324) Use of migraine medications during pregnancy and among women of childbearing age
Favorite
8:00 AM – 6:00 PM
CEST
(325) Use of population-based real world data sources and disease specific registries to conduct post approval pregnancy safety studies for a biologic indicated for a complex, uncommon indication - challenges and opportunities
Favorite
8:00 AM – 6:00 PM
CEST
(326) Use of the novel antiviral PAXLOVID for COVID-19 during pregnancy: methodological considerations for defining the baseline period across treated and untreated comparator cohorts
Favorite
8:00 AM – 6:00 PM
CEST
(327) Use of Weight-Loss Medications Among Pregnant People in the Optum Research Database
Favorite
8:00 AM – 6:00 PM
CEST
(328) Using Claims and Electronic Health Records for Pregnancy Safety Studies: A Targeted Review of Validated Algorithms.
Favorite
8:00 AM – 6:00 PM
CEST
(329) Using Real-World Data to Quantify the Rate of Unintended Pregnancies and Specified Adverse Events in Women Prescribed Oral Levonorgestrel 30µg or Levonorgestrel Implant
Favorite
8:00 AM – 6:00 PM
CEST
(330) A Comparison of Natural Language Processing (NLP) vs Clinician Review for Identification of Myocarditis Cases Following Vaccination with mRNA-1273
Favorite
8:00 AM – 6:00 PM
CEST
(331) Applicability of Selected Brighton Collaboration Case Definitions in Prospective Hospital-Based Safety Surveillance for Covid-19 Vaccines, Addis Ababa, Ethiopia
Favorite
8:00 AM – 6:00 PM
CEST
(332) Associations Between the Latest Received Dose of mRNA COVID-19 Vaccine Product and Chronic or Other Types of Urticaria: Nationwide Registry-Based Cohort Study in Denmark
Favorite
8:00 AM – 6:00 PM
CEST
(333) Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in South Korea
Favorite
8:00 AM – 6:00 PM
CEST
(334) Comparative Seroprevalence Analysis of COVID-19 Vaccination Strategies: Insights from a Multicenter Study in Castilla-Leon, Spain
Favorite
8:00 AM – 6:00 PM
CEST
(335) COVID-19 and influenza vaccine co-administration among older U.S. adults
Favorite
8:00 AM – 6:00 PM
CEST
(336) Current Approaches in Post-Approval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature
Favorite
8:00 AM – 6:00 PM
CEST
(337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication
Favorite
8:00 AM – 6:00 PM
CEST
(338) Effectiveness Evaluation of the Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey for Healthcare Professionals and Vaccinees
Favorite
8:00 AM – 6:00 PM
CEST
(339) Eighteen-month follow-up cohort study of post-vaccination COVID-19 myocarditis in France compared with other forms of myocarditis
Favorite
8:00 AM – 6:00 PM
CEST
(340) Epidemiology of Thrombotic Thrombocytopenia Syndrome before, during and post COVID-19 pandemic: English sentinel network cohort studies
Favorite
8:00 AM – 6:00 PM
CEST
(341) Evaluating impact of time-varying confounders in self-controlled risk interval analysis in a vaccine-safety cohort event monitoring-based simulation study
Favorite
8:00 AM – 6:00 PM
CEST
(342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Favorite
8:00 AM – 6:00 PM
CEST
(343) Healthcare utilization among SARS-CoV-2 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(344) Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe
Favorite
8:00 AM – 6:00 PM
CEST
(345) Mapping Genetic and Molecular Contributions to Vaccine Adverse Reactions: a systematic review of observational studies
Favorite
8:00 AM – 6:00 PM
CEST
(346) Measuring Association of Acute Disseminated Encephalomyelitis and Transverse Myelitis following COVID-19 vaccination using a Self-Controlled Case Series Analysis of Real-World Linked Data
Favorite
8:00 AM – 6:00 PM
CEST
(347) Methodological considerations for the design and implementation of real-world vaccine-related studies in low- and middle-income countries
Favorite
8:00 AM – 6:00 PM
CEST
(348) Multimodal surveillance and the importance of enabling gender-based risk stratification capabilities in real world data
Favorite
8:00 AM – 6:00 PM
CEST
(349) Patient-level prognostic models for COVID-19 vaccine effectiveness and safety: a systematic review
Favorite
8:00 AM – 6:00 PM
CEST
(350) Predicting Recovery Status of COVID-19 Vaccinated Patients with Natural Language Processing Approaches
Favorite
8:00 AM – 6:00 PM
CEST
(351) Preliminary Findings from a Feasibility and Capacity Assessment of Truveta® Studio using Flu Vaccine as Example: A Near Real-Time Electronic Health Records Database with Potential to Monitor Post-Approval Vaccine Safety
Favorite
8:00 AM – 6:00 PM
CEST
(352) Quantifying Bias in COVID-19 Vaccine Effectiveness (VE) Estimates Due to Missing Information on Prior SARS-CoV-2 Infection: an Assessment Using Data from the European COVIDRIVE Study
Favorite
8:00 AM – 6:00 PM
CEST
(353) Rare adverse events of interest following vaccination: Strengths and weaknesses of a national data resource compared to the national sentinel network database
Favorite
8:00 AM – 6:00 PM
CEST
(354) Real-world Nuvaxovid COVID-19 vaccine safety profile after first 100,000 doses in Australia
Favorite
8:00 AM – 6:00 PM
CEST
(355) Relative effectiveness (rVE) of the high-dose vs. standard-dose influenza vaccines in the French National health data system (SNDS) for people aged 65+ living in community, obtained using two approaches based on the propensity score
Favorite
8:00 AM – 6:00 PM
CEST
(356) Risk of Encephalitis and Meningitis After COVID-19 Vaccination in South Korea: a Self-controlled Case Series Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(357) Risks of Cardiovascular Events Following COVID-19 Vaccination – Results From a Nationwide Cohort Study of 8 Million Swedish Adults
Favorite
8:00 AM – 6:00 PM
CEST
(358) Safety Monitoring of Bivalent COVID-19 mRNA Vaccines Among Recipients 6 months and Older in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(359) Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European Healthcare Data Sources: Methods and Results of the Second Study Feasibility Assessment
Favorite
8:00 AM – 6:00 PM
CEST
(360) Feasibility of Prospective Real-World Studies to Fulfill Regulatory Commitments and Requirements in Oncology within the United States (US)
Favorite
8:00 AM – 6:00 PM
CEST
(361) Sex Inequity in Access to Safe Vaccination: A Sex Disaggregated Comparative Analysis of Vaccine Safety Surveillance Reports and Social Media Vaccine-Related Health Mentions.
Favorite
8:00 AM – 6:00 PM
CEST
(362) Stroke Risk Following Receipt of High-Dose/Adjuvanted Influenza Vaccinations Among U.S. Adults Aged ≥65 Years; 2016-2019
Favorite
8:00 AM – 6:00 PM
CEST
(363) The Association between COVID-19 Vaccines and Menstrual Disorders: A Systematic Review.
Favorite
8:00 AM – 6:00 PM
CEST
(364) The Importance of Standardization in Observed-to-Expected Analysis: Using COVID-19 Vaccine Adverse Event as an Example.
Favorite
8:00 AM – 6:00 PM
CEST
(365) Tokenization and linkage of state vaccine registry data to improve determination of COVID-19 vaccination status in a large administrative claims database
Favorite
8:00 AM – 6:00 PM
CEST
(366) Trends of COVID-19 Vaccine Adverse Event Following Immunization (AEFI): A One-year Retrospective Review Using the Passive Surveillance Data in the Nigerian National Database (Vigiflow).
Favorite
8:00 AM – 6:00 PM
CEST
(367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses
Favorite
8:00 AM – 6:00 PM
CEST
(368) Vaccine Cohort Event Monitoring: Enhancement of Safety Data Collection
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT01) Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT02) A prospective cohort study of risk factors associated with prostate cancer incidence in predominantly low-income Black Americans
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT03) Advancing Health Equity in Europe: A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT04) Comparing the Risk of Metoprolol-Related Adverse Drug Events Between Women and Men with Heart Failure Using Effectiveness Outcomes as a Proxy: a Population-Based Cohort Study using CPRD
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT05) Interpreting Effect Estimates Across Racial and Ethnic Categories in Propensity Score-Based Analyses: An Application in US Medicare Beneficiaries Initiating Antidiabetic Medications
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT06) Racial diversity and multimodal safety assessments: limitations of spontaneous reports data and the importance of advancing race-based risk stratification capabilities in real world data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT07) What we owe to patients: A systematic literature review into reporting of potential biases in clinical decision support tools that use AI to personalise care in viral hepatitis
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT08) Enhancing Early Detection of Medical Device Safety Signals: A Case Study of Implantable Cardioverter Defibrillator Leads
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT09) Hospital readmissions among patients with atrial fibrillation undergoing catheter ablation using ThermoCool SmartTouch/ThermoCool SmartTouch SF Catheter with CARTO 3 System versus TactiCath Catheter with EnSite System
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT10) Impact of longitudinal data completeness on risk adjustment and outcome evaluation in hospitals database
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT11) Using Electronic Health Record Data and Neural Network to Predict 90-day Readmission after Peripheral Vascular Intervention: Can it Match and Augment the Capacity of Clinical Registry?
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT12) Racial and Ethnic Disparities in Robot-Assisted Radical Prostatectomy: Physician-level Mechanisms
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT13) Does an additional gold or silver alloy provide any benefit over copper-only intrauterine devices? Insights from the EURAS-LCS12 study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT14) All Enabling Technology is not created equal: comparing outcomes of computer assisted fluoroscopic hip navigation versus robotic-assisted total hip arthroplasty
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT15) Transcatheter and Surgical Aortic Valve Implantation in the Management of Aortic Stenosis between 2010 and 2022: a French Nationwide Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT16) Paternal metformin use before pregnancy and risk of congenital malformations: a cross-national cohort study in Norway and Taiwan
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT17) Trajectories for migraine medication in pregnancy and neurodevelopmental outcomes in offspring - a nationwide registry-based study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT18) Concomitant Use of Antidepressants and Benzodiazepines During Pregnancy and Associated Risk of Congenital Malformations in Offspring: Population Based Cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT19) Estimating the Risk of Gestational Diabetes Mellitus Associated With Antidepressant Continuation During Pregnancy Using a Treatment Decision Study Design
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT20) Prevalence and treatment of chronic hypertension during pregnancy in a U.S. cohort, 2008-2021
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT21) Changes in adverse event reporting of neurodevelopmental disorders after maternal valproate exposure, following a major scientific publication and regulatory decisions, a contribution of the ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT22) Associations between Dose of Prescribed Opioid Analgesic Exposure During Pregnancy and Adverse Birth Outcomes and Early Mortality: A Population-Based Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT23) Evaluating performance and methodologies of machine learning and conventional pharmacoepidemiologic modeling to identify pregnant individuals at risk of giving birth to children with major congenital malformations
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT24) Data Mining for Adverse Events of Montelukast in Children and Adolescents: A Tree-Based Scan Statistics Analysis of Swedish Nationwide Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT25) Proton Pump Inhibitors Use and Risk of Inflammatory Bowel Disease in Children: A Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT26) Association between childhood exposure to nuclear medicine and the risk of malignancy: sibling control and population-based cohort study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT27) Severe Cutaneous Adverse Reactions Associated with Antibiotics in Pediatric Patients
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT28) How far can we go with Federated Meta-Analytic Approaches in Rare Diseases and Special Populations: A Case Example in Pediatric Pulmonary Arterial Hypertension for Regulatory Purposes
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT29) Trends in the prescribing of controlled substances to children and young adults enrolled in Medicaid, 2001-2019
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT30) Pediatric Utilization of New Molecular Entities (NMEs): A Summary of Early Post-marketing Uptake in the Sentinel Distributed Database
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT31) Real-world Research on Drug Safety Based on Quantitative Structure-Activity Relationship: A Case Study on Pediatric Drug-Induced Immune Thrombocytopenia
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT32) Important Tool in our Rare Disease Toolbox: Hybrid Retrospective-Prospective Natural History Studies Serve Well as External Comparators for Rare Disease Studies
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT33) Natural history of dermatomyositis and polymyositis in adults and paediatric populations: a network cohort study part of DARWIN EU®
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT34) Characteristics of Patients with ATTR Amyloidosis and Methodological Approaches for Establishing Clinical Subtype in the Netherlands
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT35) Leverage of an EHR Database to Estimate Prevalence and Incidence of Lymphatic Malformations (a Rare Disease) in the UK
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT36) Assessing Clinical Evidence for the Incorporation of Technologies in Ultra-rare Diseases in Brazil: A Decade of CONITEC Reports
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT37) Identifying women of childbearing age with Multiple Sclerosis in six European healthcare data sources - A contribution from the IMI-ConcePTION project
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT38) Estimating period prevalence: comparing methods to describe a rare disease population
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT39) Building Patient Journeys for Prader-Willi Syndrome Patients: Insights from Electronic Health Records Through Natural Language Processing
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT40) Incident benzodiazepine and Z-drug use and subsequent risk of serious infections
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT41) Current Applications of Machine Learning for Causal Inference in Healthcare Research using Observational Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT42) Signal Detection using Real World Data - Anticipating Serious Outcomes in Cancer Patients through Thresholds Ranges derived from US-based Claims Data
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT43) Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective.
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT44) Real-World Trends in SARS-CoV-2 Antibody Levels and Their Link to Subsequent COVID-19 in the United States
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT45) High-throughput sequence symmetry analysis to detect Beta-Blocker induced prescribing cascades
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT46) Tree-based Scan Statistics to Identify Drug Repurposing Signals: a Test Case using Sodium-Glucose Cotransporter-2 Inhibitors
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT47) The Effect of Sodium Glucose Cotransporter-2 Inhibitors on HbA1c Variability and Acute Kidney Injury: A Causal Mediation Analysis
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT48) Effects of Sequential vs Single Pneumococcal Vaccination on Cardiovascular Diseases among Older Adults: a Population-based Cohort Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT49) Quality of and methodological heterogeneity in COVID-19 Vaccine safety studies – Case study of the myocarditis safety signal
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT50) Risk of New-Onset Seizures Following Immunization against COVID-19 in South Korea: A Self-Controlled Case-Series Study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT51) Signal Monitoring for Adverse Events Following Immunization with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT52) Immunomodulatory treatment and immune responses to COVID-19 booster shots in patients with autoimmune rheumatic diseases: Results from the Covid-19 VaccinE Response in Rheumatology patients (COVER) study
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT53) Initial Observations on RSV Vaccine Use in Pregnant Patients
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT54) Special Populations Addressed in Vaccines Approved via the European Medicines Agency
Favorite
8:00 AM – 6:00 PM
CEST
(BSPOT55) Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Favorite
Wednesday, August 28, 2024
8:00 AM – 1:30 PM
CEST
(001) A comparison of regulatory frameworks for real-world data (RWD) collection within Early Access Programs (EAP) in the US, EU and Japan
Favorite
8:00 AM – 1:30 PM
CEST
(002) Breaking the Code: Patient Associations' Perception on Adverse Drug Reaction Reporting in Portugal
Favorite
8:00 AM – 1:30 PM
CEST
(003) Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research
Favorite
8:00 AM – 1:30 PM
CEST
(004) Challenges of multi-country post-authorisation safety studies for surveillance of new medical products
Favorite
8:00 AM – 1:30 PM
CEST
(005) Challenges, Lessons Learned and Implications for Improvement in Employing Drug Utilization Studies to Evaluate the Effectiveness of Additional Risk Minimization Measures (aRMMs)
Favorite
8:00 AM – 1:30 PM
CEST
(006) Comparative analysis of European healthcare systems: insights for selecting countries when designing Post-Authorization Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(007) Comparative Analysis of Medicines Under Additional Monitoring in the European Union and Bulgaria
Favorite
8:00 AM – 1:30 PM
CEST
(008) Comparing regulatory guidance on risk mitigation (or RMM) studies and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies (RIMES) checklist
Favorite
8:00 AM – 1:30 PM
CEST
(009) Completion and reporting rates of paediatric clinical trials conducted as part of an EU Paediatric Investigation Plan.
Favorite
8:00 AM – 1:30 PM
CEST
(010) Comprehensive Analysis of Pharmacovigilance Inspections Practices: Focus on QPPV Responsibilities in the Pharmaceutical Industry in Saudi Arabia
Favorite
8:00 AM – 1:30 PM
CEST
(011) Does Expedited Regulatory Approval Predict the Therapeutic Value of Drugs? A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(012) Drivers and Methodological Considerations Associated with the Acceptability of Real-World Evidence for Effectiveness/Efficacy by Regulators and HTAs: Evidence from North America, Europe, and Australia
Favorite
8:00 AM – 1:30 PM
CEST
(013) Effectiveness of additional risk minimisation measures for valproate among healthcare professionals and patients: a cross-sectional survey in six European countries
Favorite
8:00 AM – 1:30 PM
CEST
(014) Experiences and perceptions of patients and healthcare professionals with advanced practice partnership agreements between Family Medicine Group pharmacists and healthcare professionals
Favorite
8:00 AM – 1:30 PM
CEST
(015) Experts’ opinion on data quality assessments for multi-database pharmacoepidemiologic studies: A qualitative analysis
Favorite
8:00 AM – 1:30 PM
CEST
(016) FDA REMS: Characterizing Burdens and Case Application of a Novel Integrated Ethical Framework
Favorite
8:00 AM – 1:30 PM
CEST
(017) Forging a Path for Transporting Real-World Evidence: Existing Applications & Proposed Practices
Favorite
8:00 AM – 1:30 PM
CEST
(018) Guidelines for the Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in Pharmacovigilance (READUS-PV)
Favorite
8:00 AM – 1:30 PM
CEST
(019) Health Technology Assessment in the Asia-Pacific Region: A Systematic Review of Current Practices, Challenges, and Future Directions
Favorite
8:00 AM – 1:30 PM
CEST
(020) Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: A comparison Between Manufacturer and Common Drug Review analyses
Favorite
8:00 AM – 1:30 PM
CEST
(021) How to improve Patient centricity in Benefit-Risk Assessments (BRA)?
Favorite
8:00 AM – 1:30 PM
CEST
(022) Impact of Mobile Health (mHealth) Technologies on Medication Adherence and Symptoms Improvement in Patients Receiving Oral Anti-Cancer Agents: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(023) Impact of pharmacovigilance interventions targeting fluoroquinolones on systemic antimicrobial drug use and health outcomes in the Netherlands
Favorite
8:00 AM – 1:30 PM
CEST
(024) Impact of regulatory interventions on immediate release fentanyl and alternatives use in Spain: an interrupted time-series analysis
Favorite
8:00 AM – 1:30 PM
CEST
(025) Improving the Quality of Drug Safety Review Reports: SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(026) Medication Errors After Methotrexate Administration. An Analysis of EudraVigilance Reports Before and After EU Referral
Favorite
8:00 AM – 1:30 PM
CEST
(027) More-EUROPA (More Effectively Using Registries) – A cross-sectional survey assessing evidence needs around the introduction of new medicines
Favorite
8:00 AM – 1:30 PM
CEST
(028) Overview of regulations for INN prescribing and substitution, with implications for the implementation of crossborder ePrescription and eDIspensation services in countries of the European Union.
Favorite
8:00 AM – 1:30 PM
CEST
(029) Patient and Public Involvement in pharmacoepidemiological research: an environmental scan
Favorite
8:00 AM – 1:30 PM
CEST
(030) Pharmacogenomics-Pharmacovigilance Project: SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(031) Proactive Safety Monitoring of Recent Registered Medicinal Products in Saudi Arabia: the SFDA Experience
Favorite
8:00 AM – 1:30 PM
CEST
(032) Race and Ethnicity Variables in Real-World Data: Implications for Reproducibility in Pharmacoepidemiology.
Favorite
8:00 AM – 1:30 PM
CEST
(033) Review of Pharmacovigilance Practice of Biosimilars in Japan
Favorite
8:00 AM – 1:30 PM
CEST
(034) Scoping Review of the Use of Post-marketing Database Studies (PMDS) as an Additional Pharmacovigilance Activity of Risk Management Plans in Japan
Favorite
8:00 AM – 1:30 PM
CEST
(035) Study Design Considerations for Real-world Observational Studies Supporting Pre-Approval Regulatory Decision-making in China
Favorite
8:00 AM – 1:30 PM
CEST
(036) The ICH E9(R1) Estimand Framework in the Context of Real-World Data and Observational Studies
Favorite
8:00 AM – 1:30 PM
CEST
(037) The public health impact of suspending cyproterone acetate (2mg)/ethinylestradiol (35µg) in France: A predictive modelling technique to estimate adverse drug reactions prevented by regulatory action
Favorite
8:00 AM – 1:30 PM
CEST
(038) Unlocking Insights: Lesson Learned from the Tokenization of a Psoriasis Trial
Favorite
8:00 AM – 1:30 PM
CEST
(039) Use of Drug Use Evaluations by Australia’s National Reimbursement Agency to Assess Quality of Medicines Use: A Document Analysis Study
Favorite
8:00 AM – 1:30 PM
CEST
(040) Using Real-World Evidence for Clinical Drug Development to Address the Gap Between Marketing Authorization and Reimbursement in European Countries
Favorite
8:00 AM – 1:30 PM
CEST
(041) Utilizing the Delphi Consensus Method to Enhance Educational Materials for Healthcare Practitioners: A Case Study with Eylea
Favorite
8:00 AM – 1:30 PM
CEST
(042) What are the main experiences and treatment preferences of people living with achondroplasia and their caregivers?
Favorite
8:00 AM – 1:30 PM
CEST
(043) “Effect Of Pharmacological Interventions On Liver Function Parameters In Patients With NAFLD/NASH: A Systematic Review and Network meta-Analysis”
Favorite
8:00 AM – 1:30 PM
CEST
(044) A Comprehensive Meta-Analysis Assessing the Diagnostic Accuracy of Non-invasive Markers to Discriminate NAFLD and NASH
Favorite
8:00 AM – 1:30 PM
CEST
(045) Assessment of Readiness to Change in Individuals with Alcoholic Liver Disease: A Cross-Sectional Study in Indian Settings
Favorite
8:00 AM – 1:30 PM
CEST
(046) Associations between Laboratory Results and Mortality in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Diabetes and Antihypertensive Drug Status.
Favorite
8:00 AM – 1:30 PM
CEST
(047) Characteristics and prevalence of potential inappropriate proton-pump-inhibitors users among older adults in Portugal: A nationwide retrospective study
Favorite
8:00 AM – 1:30 PM
CEST
(048) Cirrhosis Risk Prediction in individuals with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Favorite
8:00 AM – 1:30 PM
CEST
(050) Compared to Thiopurines and Tumor Necrosis Factor Inhibitors Novel Biologics Are Associated with Reduced Risk of Non-Melanoma Skin Cancer Among Patients with Inflammatory Bowel Disease
Favorite
8:00 AM – 1:30 PM
CEST
(051) Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: Impact of Study Design Differences on Treatment Effect
Favorite
8:00 AM – 1:30 PM
CEST
(052) Drug Repurposing in Crohn’s Disease using Danish real-world data
Favorite
8:00 AM – 1:30 PM
CEST
(053) Identification of Cohorts for Ulcerative Colitis, Diabetes, and Small Cell Lung Cancer With Corresponding Demographic and Geographic Distributions From a Nationally Representative U.S. Pharmacy Database
Favorite
8:00 AM – 1:30 PM
CEST
(054) Incidence Rates of Severe Acute Liver Injury Associated with Hepatotoxic Medication Combinations: Approach to Inform Future Drug-Drug Interaction Studies
Favorite
8:00 AM – 1:30 PM
CEST
(055) Measuring the Use of TNF-alpha Inhibitors in Patients with Ulcerative Colitis: Optimization of Washout Period Duration and Observability
Favorite
8:00 AM – 1:30 PM
CEST
(056) Non-Alcoholic Steatohepatitis (NASH) as a Risk Factor in Hepatocellular Carcinoma (HCC) Development
Favorite
8:00 AM – 1:30 PM
CEST
(057) Spatial-Temporal Patterns In Biologic Prescriptions For Inflammatory Bowel Diseases In The Public Healthcare System In Brazil
Favorite
8:00 AM – 1:30 PM
CEST
(058) Surgery for Chronic Diverticular Disease - Incidence and Predictors
Favorite
8:00 AM – 1:30 PM
CEST
(059) The Incidence of Immune Checkpoint Inhibitor-Related Hepatotoxicity (ICH) in a Real-World Setting: A Retrospective Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(060) Addressing Drug-Related Issues in Elderly Patients: A Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(062) Assessment of Drug Therapy Satisfaction Using Treatment Satisfaction with Medicines Questionnaire (SATMED Q)
Favorite
8:00 AM – 1:30 PM
CEST
(063) Association between Polypharmacy and the Risk of Chronic Kidney Disease in the Elderly Patients
Favorite
8:00 AM – 1:30 PM
CEST
(064) Battle of the Bisphosphonates: Global Utilization Trends for Osteoporosis between 2011 and 2022
Favorite
8:00 AM – 1:30 PM
CEST
(065) Bisphosphonates versus Denosumab: Assessing the Risk of Heart Failure in a Nationwide Retrospective Cohort Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(066) Changes in long-term glucocorticoid use among older adults after new diagnosis of late-onset rheumatoid arthritis
Favorite
8:00 AM – 1:30 PM
CEST
(067) Clinical outcomes of discontinuing long-term opioid therapy among older cancer survivors in nursing homes
Favorite
8:00 AM – 1:30 PM
CEST
(068) Contemporary Management of Patients After Hip Fracture. A Population-Based Cohort of Over 120.000 Patients in Spain.
Favorite
8:00 AM – 1:30 PM
CEST
(069) Denosumab Data Cleaning Algorithm to Inform Exposure Measurement and Study Inclusion: Results from Two International Databases
Favorite
8:00 AM – 1:30 PM
CEST
(070) Disability Phenotypes among Medicare Beneficiaries with Dementia: Implications for Longitudinal Confounding Control, Risk Stratification, and Comparative Effectiveness Research
Favorite
8:00 AM – 1:30 PM
CEST
(071) Discontinuation of bisphosphonates in older people with complex health needs: self-controlled case series to assess fracture risk
Favorite
8:00 AM – 1:30 PM
CEST
(072) Drug Holiday of Oral Bisphosphonates and Mortality following Hip Fracture: A Population-based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(073) Effects of AI-Assisted Drug Therapy Management on Medication-Related Issues in Elderly Patients: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(074) Identification of Inappropriate Prescribing in Elderly Population Using Medication Appropriateness Index (MAI) and Beer’s Criteria
Favorite
8:00 AM – 1:30 PM
CEST
(075) Impact of Awareness of Osteoporosis and BMD Testing on Osteoporosis Medication Use in Elderly Men and Women with Osteoporosis
Favorite
8:00 AM – 1:30 PM
CEST
(076) Incidence of opioid dose tapering among older adults enrolled in Medicare
Favorite
8:00 AM – 1:30 PM
CEST
(077) Large scale propensity score matching with time-stratification in older women with or without fractures in the UK
Favorite
8:00 AM – 1:30 PM
CEST
(078) Lifetime risk of fracture among postmenopausal women with osteoporosis and at high risk of fracture
Favorite
8:00 AM – 1:30 PM
CEST
(079) Medication Use Patterns Among Older Adults With Obstructive Sleep Apnea With and Without Comorbid Insomnia
Favorite
8:00 AM – 1:30 PM
CEST
(080) Opioid Deprescribing Rates in Older Adults with Frailty and Risk Factors for Prolonged Use after an Acute Fracture
Favorite
8:00 AM – 1:30 PM
CEST
(081) Patterns of Concurrent Opioid and Benzodiazepine Use Discontinuation among Medicare Beneficiaries 2016-2018
Favorite
8:00 AM – 1:30 PM
CEST
(082) Prevalence And Patterns of Drug-Related Problems Associated with Polypharmacy in Elderly Patients with Heart Failure: A Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(083) Trajectories of Analgesic Agent Use and Adverse Clinical Outcomes Among Older Adults: a Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(084) Trends in Central Nervous System Medication Use among Assisted Living Residents with Cognitive Impairment: Variation by Presence of Dementia Care and the COVID-19 Pandemic
Favorite
8:00 AM – 1:30 PM
CEST
(085) An Assessment of Use and Comparative Safety of GLP-1 Receptor Agonists in the Real-world Setting, 2017-2023
Favorite
8:00 AM – 1:30 PM
CEST
(086) Applying Natural Language Processing of Clinical Notes to Determine Social Determinant Risk Factor Status for Patients Receiving Glucagon-Like Peptide-1 Agonist Treatment
Favorite
8:00 AM – 1:30 PM
CEST
(087) Assessment of the Long-Term Stability of Drug Safety Signals between Frequency and Bayesian-based methods for Glucagon-like Peptide-1 Receptor Agonists
Favorite
8:00 AM – 1:30 PM
CEST
(088) Association of Glucagon-Like Peptide-1 Receptor Agonists with Parkinson’s Disease: Scandinavian Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(089) Characteristics of Glucagon-Like Peptide-1 Agonist Prescriptions for Weight Loss in the Real-World Setting
Favorite
8:00 AM – 1:30 PM
CEST
(090) Characteristics of Initial Prescription Dispensations Among Individuals Newly Prescribed GLP-1 Medications in a National Retail Pharmacy Database
Favorite
8:00 AM – 1:30 PM
CEST
(091) Characterizing the use of weight loss medications in people with obesity-related asthma in the All of Us Research Program
Favorite
8:00 AM – 1:30 PM
CEST
(092) Comparing Healthcare Utilization and Cost in Empagliflozin vs GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease
Favorite
8:00 AM – 1:30 PM
CEST
(093) Effectiveness of GLP-1 Receptor Agonists on Bodyweight Among Patients with Type-2 Diabetes Mellitus: Emulation of Five Randomized Clinical Trials Using Electronic Medical Records
Favorite
8:00 AM – 1:30 PM
CEST
(094) Effectiveness of the GLP-1 Receptor Agonists Approved to Manage Overweight and Obesity: An Emulation of the STEP 8 Trial Using Electronic Medical Records
Favorite
8:00 AM – 1:30 PM
CEST
(095) Gastrointestinal Adverse Events with Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetes: A Comprehensive Meta-analysis of Randomised Controlled Trials and Refining Signals through Pharmacovigilance Analysis.
Favorite
8:00 AM – 1:30 PM
CEST
(096) GLP1 comparative effectiveness against dementia onset in a large, multi-site cohort of type 2 diabetes patients: a trial emulation approach with targeted learning
Favorite
8:00 AM – 1:30 PM
CEST
(097) Real-World Patterns in GLP-1 RA Switching from 2018-2023 in the US
Favorite
8:00 AM – 1:30 PM
CEST
(099) Treatment Trends in Youth-Onset Type 2 Diabetes: Changing Landscape After GLP-1RA Approval
Favorite
8:00 AM – 1:30 PM
CEST
(100) Trends in Clinical Characteristics and Prescribing Patterns for GLP-1 Receptor Agonists and GIPs, 2015–2023
Favorite
8:00 AM – 1:30 PM
CEST
(101) Use of SGLT2 inhibitors vs. GLP-1 RAs and Asthma Exacerbation in Patients with Diabetes and Asthma – A target Trial Emulation Study
Favorite
8:00 AM – 1:30 PM
CEST
(102) Utilization of drugs with weight loss effect in Norway 2017-2023
Favorite
8:00 AM – 1:30 PM
CEST
(103) Weight Loss Medication Prescribing Patterns: Real-World Data Analysis from 2015 to 2023
Favorite
8:00 AM – 1:30 PM
CEST
(104) Determining the cost-effectiveness of pre-emptive genetic testing: an umbrella review
Favorite
8:00 AM – 1:30 PM
CEST
(105) Prescription Medicine Price Comparison of Employer-Sponsored Health Insurance versus Public Procurement System Used in The National Health Insurance in Indonesia
Favorite
8:00 AM – 1:30 PM
CEST
(106) Prevalence, incidence rate and attributable healthcare costs of four major disease groups in Denmark: A nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(107) Bridging the Gap and Ensuring Quality: Enhancing Real-World Data through Quality Control Implementation of an African Patient Population
Favorite
8:00 AM – 1:30 PM
CEST
(108) Comparing the Association of Social Determinants of Health between Hypertension, Migraine, and Coexisting Hypertension and Migraine in U.S. Adults Using Medical Expenditure Panel Survey Data (2013-2019)
Favorite
8:00 AM – 1:30 PM
CEST
(109) Measuring Health Trends of Transgender People Using Real World Data in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(110) Postpartum Depression and Infant Vaccination Completion: A Real-World Data and Health Equity Perspective
Favorite
8:00 AM – 1:30 PM
CEST
(111) Prevalence of Polypharmacy, Multimorbidity and Association with Mortality in Older Aboriginal and Torres Strait Islander People.
Favorite
8:00 AM – 1:30 PM
CEST
(112) Racial Disparities in Breast Cancer Management Pre- and Post-COVID-19: Unmet Needs in Health Equity
Favorite
8:00 AM – 1:30 PM
CEST
(113) Racial disparities in survival among low-income populations with lung, breast, prostate or colorectal cancers across the Southeastern United States
Favorite
8:00 AM – 1:30 PM
CEST
(114) Racial Disparity in Comorbidity Risk Profiles of Early-Onset Liver Cancer: A Case-Control Study Based on the University of California Healthcare Data Warehouse
Favorite
8:00 AM – 1:30 PM
CEST
(115) A Critical Methodological Appraisal of Studies Assessing Computerized Clinical Decision Support Systems (CDSS) Success in Improving Prescription Safety in Patients with Low Levels of Kidney Function
Favorite
8:00 AM – 1:30 PM
CEST
(116) Case-Identifying Algorithms of Chronic Kidney Disease for Real-World Evidence Research: A Targeted Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(117) Effectiveness of pharmacist intervention in patients with pre-end-stage renal disease (pre-ESRD): A prospective study
Favorite
8:00 AM – 1:30 PM
CEST
(118) Ethnicity and polypharmacy in people with chronic kidney disease: a pharmacoepidemiologic perspective
Favorite
8:00 AM – 1:30 PM
CEST
(120) Living alone and prognosis in elderly patients with chronic kidney disease: a nationwide study from Denmark
Favorite
8:00 AM – 1:30 PM
CEST
(121) Mortality associated with use of etelcalcetide versus cinacalcet for the treatment of secondary hyperparathyroidism in patients in haemodialysis: a population based study in Lazio, Italy
Favorite
8:00 AM – 1:30 PM
CEST
(122) Multisource Overview on Proton Pump Inhibitors-Associated Acute Kidney Injury
Favorite
8:00 AM – 1:30 PM
CEST
(123) Predictors of post-operative acute kidney injury after colorectal cancer surgery
Favorite
8:00 AM – 1:30 PM
CEST
(124) Risk Modeling to Obtain Individualized Estimates of Ibuprofen Associated Acute Kidney Injury in Hospitalized Patients
Favorite
8:00 AM – 1:30 PM
CEST
(125) Risk of Acute Kidney Injury with Direct Oral Anticoagulants Compared with Warfarin: Population-based analysis.
Favorite
8:00 AM – 1:30 PM
CEST
(126) Risk of Peritonitis in Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis
Favorite
8:00 AM – 1:30 PM
CEST
(127) Selective reporting of renal effects in clinical trials with cyclooxygenase-2 inhibitors
Favorite
8:00 AM – 1:30 PM
CEST
(128) Sex-specific temporal trends in prevalence and incidence of chronic kidney disease: a Danish population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(129) Short- and Long-Term Associations of Hyperkalemia-related Events on Serum Potassium Time Courses in Patients with Chronic Kidney Disease: A Retrospective Cohort Study Using Electronic Health Records Data from the United States
Favorite
8:00 AM – 1:30 PM
CEST
(130) A comparison of the descriptive epidemiology derived from the GOLD and Aurum datasets in the Clinical Practice Research Datalink
Favorite
8:00 AM – 1:30 PM
CEST
(131) A Flexible Open-Source Analytic Pipeline for Self-Controlled Analysis of Real World Data
Favorite
8:00 AM – 1:30 PM
CEST
(132) A Framework for Rapid Analysis of Real-World Data in Safety Signal Assessment
Favorite
8:00 AM – 1:30 PM
CEST
(133) A novel estimation method for adjusting virtual inconsistency in a star-shaped network meta-analysis: an illustration of a case study
Favorite
8:00 AM – 1:30 PM
CEST
(134) A review of recommendations in guidelines on missing data in prediction modelling
Favorite
8:00 AM – 1:30 PM
CEST
(135) A semi-quantitative method to assess the likelihood of causality in observational studies
Favorite
8:00 AM – 1:30 PM
CEST
(136) A systematic review of algorithms used to identify neurodevelopmental disorders in electronic healthcare databases
Favorite
8:00 AM – 1:30 PM
CEST
(137) A Systematic Review to Summarize and Critically Appraise of Existing Phenotype Libraries Using Electronic Health Records- a FLOW study under the VAC4EU organisation
Favorite
8:00 AM – 1:30 PM
CEST
(138) An Application of Bayesian Modelling for Information Sharing in Safety Signal Detection
Favorite
8:00 AM – 1:30 PM
CEST
(139) An Evaluation of Patient Activity Definitions and Informative Censoring in Analyses of Real-World Overall Survival in Electronic Health Records (EHR) in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(140) Application of capture-recapture method to estimate prevalence with registry data
Favorite
8:00 AM – 1:30 PM
CEST
(141) Assessing Exposure to Recently Approved Medications to Inform Feasibility for Signal Identification Analyses in the FDA’s Sentinel System
Favorite
8:00 AM – 1:30 PM
CEST
(142) Assessing the potential value of commercial mortality data combined with publicly available death data for pharmacoepidemiology research
Favorite
8:00 AM – 1:30 PM
CEST
(143) Assessment of the Application of a 90-Day-Gap Rule for Mitigating Frontline Treatment Sequence Misclassification in Electronic Health Records in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(144) Comparison of multilevel propensity score estimation methods for tooth-clustered data in the evaluation of treatment effect in the presence of competing risks
Favorite
8:00 AM – 1:30 PM
CEST
(145) Critical Review of Dimensionality Reduction Approaches in Epidemiological Research
Favorite
8:00 AM – 1:30 PM
CEST
(146) Development and Indirect Validation of Patient Identification Algorithms to Identify Patients with Refractory Lupus using US Insurance Claims
Favorite
8:00 AM – 1:30 PM
CEST
(147) Development and Validation of a Novel Tool to Predict Hemoglobin A1c among Patients with Type 2 Diabetes, Using Administrative Claims Data
Favorite
8:00 AM – 1:30 PM
CEST
(148) Development and Validation of Text Mining Approach for Detecting Recurrence for Early Breast Cancer Patients: A Multi-institutional Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(149) Development of Algorithms for the Implementation and Detection of Adverse Events in Routine Electronic Data Sources
Favorite
8:00 AM – 1:30 PM
CEST
(150) Effect of Race on Classification of Atherosclerotic Risk Using A National Cardiovascular Risk Prediction Tool
Favorite
8:00 AM – 1:30 PM
CEST
(151) Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real-World Data: A Validation Study from the INVESTED-Medicare Linkage
Favorite
8:00 AM – 1:30 PM
CEST
(152) Evaluating Methods to Define Place of Residence in Administrative Data and the Impact on Observed Associations
Favorite
8:00 AM – 1:30 PM
CEST
(153) Evaluating the Accuracy of Infant Weight and Length Measurements from Electronic Health Records for Use in Maternal Vaccination Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(154) Fit-for-purpose evaluation of Real-World Data for vaccines and medicines safety studies: the INSIGHT tool
Favorite
8:00 AM – 1:30 PM
CEST
(155) Guidance for the Design of Observational Studies to Estimate the Effects of Long-term Drug Exposures
Favorite
8:00 AM – 1:30 PM
CEST
(156) High-dimensional propensity score implementation utilising electronic health records in Hong Kong
Favorite
8:00 AM – 1:30 PM
CEST
(157) Identification and Quantification of Barriers to Achieving Clinical Trial Diversity
Favorite
8:00 AM – 1:30 PM
CEST
(158) Identification of Valid Indicators for the Detection of Potentially Adverse Drug Event-Related Hospitalisations in Routine Electronic Data Sources: a RAND Survey
Favorite
8:00 AM – 1:30 PM
CEST
(159) Insomnia Symptom Prevalence in England: A Comparison of Self-Reported Data and Primary Care Records in the UK Biobank
Favorite
8:00 AM – 1:30 PM
CEST
(160) Intention to treat and on treatment exposure definition in observational safety studies: a simulation study using real world data
Favorite
8:00 AM – 1:30 PM
CEST
(161) Linking clinical trial participants to their U.S. real-world data through tokenization: a practical guide
Favorite
8:00 AM – 1:30 PM
CEST
(163) Methodological framework to conduct outcome validation in administrative or insurance claims and/or electronic healthcare record databases: a practical guide for pharmacoepidemiologists
Favorite
8:00 AM – 1:30 PM
CEST
(165) Missing data analysis methods to correct outcome mismeasurement in pharmacoepidemiological studies using electronic medical information: Methodologies and recommendations for future validation studies
Favorite
8:00 AM – 1:30 PM
CEST
(166) Model-based Meta-analysis: An Innovative and Robust Methodology for Clinical Decision Making
Favorite
8:00 AM – 1:30 PM
CEST
(167) Optimizing BMI Data Accuracy: Synergy Of Claims And EHR Databases
Favorite
8:00 AM – 1:30 PM
CEST
(168) Outcome Validation to Assess Misclassification Bias in Studies Using Electronic Healthcare Claims
Favorite
8:00 AM – 1:30 PM
CEST
(169) Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients
Favorite
8:00 AM – 1:30 PM
CEST
(170) Quantifying Bias in Claims Safety Studies Arising from Medication Samples: A Simple Simulation
Favorite
8:00 AM – 1:30 PM
CEST
(171) Quantifying the impact of different look-back period criteria to identify new users when medication adherence is poor: A study of chronic medications for opioid use disorder
Favorite
8:00 AM – 1:30 PM
CEST
(172) Reporting of Harm from Randomized Clinical Trials in Medical Publications
Favorite
8:00 AM – 1:30 PM
CEST
(173) Short-term mortality in the Danish Better Health in Late Life Cohort - A study on cohort representativeness
Favorite
8:00 AM – 1:30 PM
CEST
(174) Standardization of Coding Definitions for Sickle Cell Disease Complications: A Systematic Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(175) The Use and Implementation of Instrumental Variables in Pharmacoepidemiology: A Scoping Review
Favorite
8:00 AM – 1:30 PM
CEST
(176) Translating population-level epidemiology to patient need
Favorite
8:00 AM – 1:30 PM
CEST
(177) Validated case-identifying algorithms using Canadian administrative health data: a targeted literature review
Favorite
8:00 AM – 1:30 PM
CEST
(178) Validation of Algorithms to Identify Breast Cancer and Bladder Cancer Among Patients With Type 2 Diabetes Mellitus in United States Medicare Administrative Claims
Favorite
8:00 AM – 1:30 PM
CEST
(179) Validation of claims algorithm to identify HR+/HER2- metastatic breast cancer patients
Favorite
8:00 AM – 1:30 PM
CEST
(180) Validation of claims-based algorithms for identifying neonatal urinary tract, genital, gastrointestinal, and musculoskeletal malformations in healthcare utilization databases
Favorite
8:00 AM – 1:30 PM
CEST
(181) Validation of obstetric diagnosis and procedure codes in the Danish National Patient Registry
Favorite
8:00 AM – 1:30 PM
CEST
(182) Validation of Rhabdomyolysis in Claims Using Electronic Health Data in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(183) Validation study of the death information registered in BIFAP electronic health care records data source (Spain).
Favorite
8:00 AM – 1:30 PM
CEST
(184) Validity of Inpatient ICD 10 Codes for Heat-related Illnesses in US Medicare Data
Favorite
8:00 AM – 1:30 PM
CEST
(185) Validity of Out-of-Hospital and In-Hospital Cardiac Arrest Algorithms in the Danish National Patient Registry
Favorite
8:00 AM – 1:30 PM
CEST
(186) Who Should Be Prioritised For Primary Care Medication Review? Consensus Validation And Point Prevalence of Explicit Prescribing Indicators
Favorite
8:00 AM – 1:30 PM
CEST
(187) Will Patients engage with Digiatl Technologies as part of Routine Healthcare?
Favorite
8:00 AM – 1:30 PM
CEST
(188) Association between antidepressants and risk of withdrawal syndrome in illicit substance users: nationwide case-case-time-control study
Favorite
8:00 AM – 1:30 PM
CEST
(189) Disability and Workers’ Compensation Absences Associated with Major Depressive Disorder and the Overlap with Family Medical Leaves Among US Employees
Favorite
8:00 AM – 1:30 PM
CEST
(190) Do efficacy results obtained from randomised controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?
Favorite
8:00 AM – 1:30 PM
CEST
(191) Healthcare resource use (HRU) of patients with active relapsing multiple sclerosis (RMS) using data linkage between a phase IV study and the France's national health data system.
Favorite
8:00 AM – 1:30 PM
CEST
(192) Impact of the disability status of patients with multiple sclerosis on healthcare resource utilization and the ability to work: An analysis of the MSDS-AOK PLUS Linked Database
Favorite
8:00 AM – 1:30 PM
CEST
(193) Inflammatory Bowel Disease among Patients with Multiple Sclerosis and matched Controls: Findings from a Retrospective Cohort Study Utilizing a US Electronic Health Record Database
Favorite
8:00 AM – 1:30 PM
CEST
(194) Risk Of Cardiovascular Events Among Youths And Young Adults With Concomitant Use Of Atypical Antipsychotics With Antidepressants
Favorite
8:00 AM – 1:30 PM
CEST
(195) Systematic emulation trials to evaluate the real-world effectiveness of multiple sclerosis treatments
Favorite
8:00 AM – 1:30 PM
CEST
(196) The relative risk of infection in people with multiple sclerosis using disease-modifying treatments: a systematic review of observational studies
Favorite
8:00 AM – 1:30 PM
CEST
(197) The Risk of Hypokalemia in Patients Treated with Levetiracetam: A Comparative Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(199) A US Retrospective Claims Database Analysis: 2-year Restricted Mean Time in Buprenorphine Treatment Among People with Opioid Use Disorder
Favorite
8:00 AM – 1:30 PM
CEST
(200) Age-related risk of serious fall events associated with opioid analgesic use
Favorite
8:00 AM – 1:30 PM
CEST
(201) Association between long-term opioid use and risk of depression, suicidal ideation and sleep disorders in patients with fibromyalgia: a population-based, propensity-weighted cohort study.
Favorite
8:00 AM – 1:30 PM
CEST
(202) Association Between Rapid Opioid Dose Tapering and Polydrug Overdose Death Among High-dose, Long-term Opioid Therapy Recipients in North Carolina Between 2006-2018
Favorite
8:00 AM – 1:30 PM
CEST
(203) Association of opioid and benzodiazepine co-prescribing with adverse events among older adults with cancer
Favorite
8:00 AM – 1:30 PM
CEST
(205) Co-Administration of Oxycodone and CYP3A4-Inhibiting Calcium Channel Blockers and Opioid Overdose: Real-World Evidence from Population-based Claims Data in the United States, 2000-2020.
Favorite
8:00 AM – 1:30 PM
CEST
(206) Design Process for a Machine-Learning Opioid Overdose Prediction and Risk Stratification E-Tool in Electronic Health Record System
Favorite
8:00 AM – 1:30 PM
CEST
(207) Disenrollment Among Commercially-Insured Individuals in the United States with Opioid Use Disorder, 2010-2019
Favorite
8:00 AM – 1:30 PM
CEST
(208) Early Opioid Use Disorder Treatment Pathways and Determinants Among the Commercially-Insured, 2010-2019
Favorite
8:00 AM – 1:30 PM
CEST
(210) Long-term prescribed opioid use after hospitalisation or emergency department presentation among opioid-naïve adults in New South Wales (NSW), Australia (2014–2020)—a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(211) Machine Learning Natural Language Processing Classifiers to Enhance Opioid Overdose Surveillance Precision
Favorite
8:00 AM – 1:30 PM
CEST
(212) Medications for Opioid Use Disorder (MOUD) Prescribing Trends in the US Ambulatory Care Settings
Favorite
8:00 AM – 1:30 PM
CEST
(213) Opioid exit plans: A systematic review on tapering strategies upon hospital discharge for non-cancer pain
Favorite
8:00 AM – 1:30 PM
CEST
(215) Opioid Use and Its Association with Clostridium difficile Infection: A Systematic Review and Meta-Analysis of Observational Studies
Favorite
8:00 AM – 1:30 PM
CEST
(216) Patterns of inpatient opioid trajectories following major or orthopaedic surgery
Favorite
8:00 AM – 1:30 PM
CEST
(217) Patterns of opioid doses to compensated Australian workers with low back pain
Favorite
8:00 AM – 1:30 PM
CEST
(218) Perceptions on treatment utilization and risk of overdose among opioid users in Kolkata: A qualitative study
Favorite
8:00 AM – 1:30 PM
CEST
(219) Person, hospital, and geographic factors associated with connection to treatment following hospital discharge for an opioid toxicity
Favorite
8:00 AM – 1:30 PM
CEST
(220) Predictors of persistent opioid use in Australian primary care: a retrospective cohort study, 2018 – 2022
Favorite
8:00 AM – 1:30 PM
CEST
(221) Preoperative opioid use and postoperative return to work following spinal surgery in workers’ compensation settings: A systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
CEST
(222) Prevalence and variations of potential hazardous opioid prescribing across the United Kingdom general practices
Favorite
8:00 AM – 1:30 PM
CEST
(223) Risk of post-surgical persistent opioid use and fractures in patients undergoing major surgery in England
Favorite
8:00 AM – 1:30 PM
CEST
(224) Use of medications for opioid use disorder in older adults
Favorite
8:00 AM – 1:30 PM
CEST
(225) A systematic review and network meta-analysis of gamification approach for attention-deficit hyperactivity disorder in children and adolescents focusing on digital therapeutics
Favorite
8:00 AM – 1:30 PM
CEST
(226) Adrenocorticotropic hormone versus prednisolone for infantile spasms: a systematic review and economic evaluation
Favorite
8:00 AM – 1:30 PM
CEST
(227) Assessment of Age-appropriateness and Acceptability of Oral Medicine Formulations for Children Less than 5 Years in a Low Income Setting
Favorite
8:00 AM – 1:30 PM
CEST
(228) Beta-blocker-associated Hypoglycemia in Pediatric Patients: Findings from the FDA Adverse Event Reporting System, National Poison Data System, Medical Literature, and Sentinel Distributed Database
Favorite
8:00 AM – 1:30 PM
CEST
(229) Characterizing incident antidepressant use in young people in Norway: pathways to treatment and follow-up in specialist healthcare
Favorite
8:00 AM – 1:30 PM
CEST
(230) Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table
Favorite
8:00 AM – 1:30 PM
CEST
(231) Characterizing inpatient electronic health records (EHR) from a large hospital network for use in neonatal pharmacoepidemiology studies in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(232) Characterizing Pediatric Members in the Sentinel Distributed Database: An Update with Data from Medicaid
Favorite
8:00 AM – 1:30 PM
CEST
(233) Development of a multivariate prognostic model to predict mortality in neonatal sepsis patients.
Favorite
8:00 AM – 1:30 PM
CEST
(234) Dosing of antidepressants in relation to body weight in children and adolescents with overweight and obesity- a population-based study
Favorite
8:00 AM – 1:30 PM
CEST
(235) Drug utilization in children at a German university hospital – Are evidence-based (off-label) dosing recommendations available?
Favorite
8:00 AM – 1:30 PM
CEST
(236) Increased Prescribing of Neuroleptics to Children in Sweden
Favorite
8:00 AM – 1:30 PM
CEST
(237) Infant Growth and Development Outcomes among Commercially Insured Infants in the United States, 2016 – 2023
Favorite
8:00 AM – 1:30 PM
CEST
(238) Influence of relative age on initiation of methylphenidate and speech therapy in children aged 5 to 10 years: a French nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(239) Off-label use of antidepressants among pediatric patients in China
Favorite
8:00 AM – 1:30 PM
CEST
(240) Off-label use of thalidomide in pediatric patients with Crohn's disease and other subtypes of inflammatory bowel disease: a literature review
Favorite
8:00 AM – 1:30 PM
CEST
(241) Pediatric cancer in the United States: a comparison of two data sources
Favorite
8:00 AM – 1:30 PM
CEST
(242) Performance of Disease Activity Monitoring in Individuals with Childhood-Onset Lupus Nephritis in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(243) Prevalence and Patterns of ADHD Medication Use Among Children, Adolescents, and Young Adults: A Two-decade Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(244) Psychotropic drug use among 0-17 year old Norwegians during 2014-2021: a nationwide register study
Favorite
8:00 AM – 1:30 PM
CEST
(245) Psychotropic Drug Utilization Patterns among Children and Adolescents in British Columbia, Canada: Sex Differences in Drug Initiation
Favorite
8:00 AM – 1:30 PM
CEST
(246) Quality assessment of medication data from routine paediatric inpatient documentation – A prerequisite for drug utilisation studies
Favorite
8:00 AM – 1:30 PM
CEST
(247) Relative age effect on ADHD diagnosis, medication prescription, and persistence: a population-based study within a birth cohort
Favorite
8:00 AM – 1:30 PM
CEST
(248) Surveillance of outcomes identified with use of biologics indicated for asthma: a comparison of events observed with pediatric utilization
Favorite
8:00 AM – 1:30 PM
CEST
(249) The importance of the analysis of multiple databanks for the valid estimation of thrombocytopenia incidence rates in children in BIFAP data source (Spain).
Favorite
8:00 AM – 1:30 PM
CEST
(250) The Pharmacotherapy Options for Attention-Deficit Hyperactivity Disorder (ADHD) in Taiwan and the Influencing Factors
Favorite
8:00 AM – 1:30 PM
CEST
(251) The real-world use of medicines for the management of haematological malignancies in paediatric populations: an international scoping review.
Favorite
8:00 AM – 1:30 PM
CEST
(252) Trends in Childhood BMI, Overweight, and Obesity among 7-year-old Girls during the Last Six Decades
Favorite
8:00 AM – 1:30 PM
CEST
(253) Trends in distal radius fractures in Japanese children 2007-2021
Favorite
8:00 AM – 1:30 PM
CEST
(254) Trends in New Use of Disease-Modifying Antirheumatic Drugs Among Children with Juvenile Idiopathic Arthritis in the United States, 2001-2022
Favorite
8:00 AM – 1:30 PM
CEST
(255) Trends of Antidepressant Use Among Children in Commercial and Public Payer Systems in the United States, 2001-2019
Favorite
8:00 AM – 1:30 PM
CEST
(256) Use of Medications with Depression and Suicidal Adverse Effects Among Children, Adolescents, and Young Adults in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(257) Within-Trial Interviews to Contextualize the Patient Experience and Supplement Clinical Outcomes Assessments in a Pivotal Trial of a Newly Described, Fatal and Ultra-Rare Pediatric Disease
Favorite
8:00 AM – 1:30 PM
CEST
(259) A Multi-Source Approach to Pregnancy and Lactation Evidence Generation in Multiple Sclerosis: The Ocrelizumab Example
Favorite
8:00 AM – 1:30 PM
CEST
(260) A systematic review of gabapentinoids use during pregnancy and effects on pregnancy and childhood outcomes: an IMI ConcePTION study
Favorite
8:00 AM – 1:30 PM
CEST
(262) Antidepressant and Psychotherapy Initiation Among Patients with New Episodes of Depression During Pregnancy
Favorite
8:00 AM – 1:30 PM
CEST
(263) Antiseizure medication use during pregnancy and the Risk of adverse neonatal birth outcomes in two Canadian provinces
Favorite
8:00 AM – 1:30 PM
CEST
(264) Cardiac Autonomic Stress Response in 6- and 12-Year-Old Children After Prenatal Selective Serotonin Reuptake Inhibitor Medication Exposure: A Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(265) Characteristics and Adverse Postpartum Psychiatric Outcomes in Women With Bipolar Disorder Who Discontinue Lithium During Pregnancy: A Swedish Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(266) Characteristics and Depression Severity Among Pregnant Women by Antidepressant Use During Pregnancy
Favorite
8:00 AM – 1:30 PM
CEST
(267) Characteristics of perinatal depression screening and trend over time in a commercial, US-based administrative claims database
Favorite
8:00 AM – 1:30 PM
CEST
(268) Comparative safety of prenatal exposure to buprenorphine versus methadone with regards to adverse neurodevelopmental outcomes
Favorite
8:00 AM – 1:30 PM
CEST
(269) Comparison of antidepressant use in normal-age and late-age pregnancies
Favorite
8:00 AM – 1:30 PM
CEST
(270) Concomitant Periconceptional Opioid Medication, Alcohol, and Tobacco Use
Favorite
8:00 AM – 1:30 PM
CEST
(271) Discontinuation patterns of antipsychotics in pregnant women: A cohort study from South Korea
Favorite
8:00 AM – 1:30 PM
CEST
(272) Emergency Department Visits due to Monoclonal Antibody Adverse Events—United States, 2004–2020
Favorite
8:00 AM – 1:30 PM
CEST
(273) Gabapentin in Pregnancy and Birth Outcomes: a Population-based Prevalence Study in Nordic Countries (EUPAS38620)
Favorite
8:00 AM – 1:30 PM
CEST
(274) Gabapentin Use During Pregnancy and the Risk of Adverse Neonatal Birth Outcomes in two Canadian provinces
Favorite
8:00 AM – 1:30 PM
CEST
(275) Gabapentinoids exposure in early pregnancy and risk of congenital anomalies: an IMI ConcePTION European case-malformed control study
Favorite
8:00 AM – 1:30 PM
CEST
(276) Intensity and duration antidepressant exposure in pregnancy and childhood growth trajectories: results from the Norwegian Mother, Father and Child Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(277) Maternal Mental Health in Focus: Real-World Data on Antidepressant Use. A Cohort Study in Catalonia.
Favorite
8:00 AM – 1:30 PM
CEST
(278) Maternal opioid use during breastfeeding and the risk of adverse infant outcomes: A nationwide cohort study among 4 million mother-child dyads
Favorite
8:00 AM – 1:30 PM
CEST
(279) Opioid Use in Pregnancy in Women with Disabilities
Favorite
8:00 AM – 1:30 PM
CEST
(280) Pregnancy and Fetal Outcomes after Maternal Exposure to Glatiramer Acetate – an Updated Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(281) Progress Towards Enrollment in a US Pregnancy Registry for Galcanezumab and Lasmiditan
Favorite
8:00 AM – 1:30 PM
CEST
(282) Reason for gabapentinoids prescribing in pregnancy: results from five European countries. A contribution from the IMI ConcePTION project
Favorite
8:00 AM – 1:30 PM
CEST
(283) Trends in antidepressant use during early pregnancy in Germany between 2005 and 2020
Favorite
8:00 AM – 1:30 PM
CEST
(284) Attitudes and barriers to deprescribing in general practice: the perspective of general practitioners.
Favorite
8:00 AM – 1:30 PM
CEST
(285) Clinical Pharmacist-Led Medication Review in Post-Acute Care: Preliminary Results of an Observational Retrospective Study
Favorite
8:00 AM – 1:30 PM
CEST
(286) Description of interventions performed by pharmacists involved in the care of older adults with neurocognitive disorders in family medicine groups in Quebec, Canada
Favorite
8:00 AM – 1:30 PM
CEST
(287) EHR-based pragmatic trial evaluating the impact of simulation intervention on high-risk prescribing to older adults by junior physicians
Favorite
8:00 AM – 1:30 PM
CEST
(288) Exploring community pharmacy services in the Gulf Region: a scoping review
Favorite
8:00 AM – 1:30 PM
CEST
(289) Highlighting The Role Of The Pharmacist In The Management Of Medication Shortages – An Exploratory Mapping Exercise To The Core Competency Framework For Pharmacists
Favorite
8:00 AM – 1:30 PM
CEST
(290) Impact of Community Pharmacist-Led Services in the Global Fight Against HIV/AIDS: A Systematic Review
Favorite
8:00 AM – 1:30 PM
CEST
(291) Interest in Use of a Mobile App for Reporting Adverse Drug Reactions: A Survey Study Among Healthcare Professionals and the Public in Indonesia
Favorite
8:00 AM – 1:30 PM
CEST
(292) Knowledge and Barriers in Medication Adherence and Prescription Appropriateness Tools: A Cross-Sectional Study in Clinical Practice
Favorite
8:00 AM – 1:30 PM
CEST
(293) Nurses’ intention to report adverse drug events, a survey using the theory of planned behavior.
Favorite
8:00 AM – 1:30 PM
CEST
(294) Optimization of Commercial Clinical Decision Support System for Inpatient Pharmacy at a Medical Center in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(295) Physicians' Attitudes Towards Initiatives to Enhance the Environmental Sustainability of Pharmaceutical Treatment
Favorite
8:00 AM – 1:30 PM
CEST
(296) Primary Care Physicians’ Views on Drug Interaction Alerts – a Questionnaire Study
Favorite
8:00 AM – 1:30 PM
CEST
(298) Are Costs Decisive in the Incorporation of Medicines for the Treatment of Ultra-rare Diseases in Brazil? Trends in Healthcare Coverage for Ultra-rare Diseases
Favorite
8:00 AM – 1:30 PM
CEST
(299) Assessing the agreement between open and closed medical claims in a rare disease cohort
Favorite
8:00 AM – 1:30 PM
CEST
(300) Assessing the feasibility of TREAT-NMD registries for characterising adult patients with SMA receiving risdiplam treatment
Favorite
8:00 AM – 1:30 PM
CEST
(301) Can riluzole use for motor neuron disease reduce risk of hospitalisation: A common data model study using Self-Controlled Case Series
Favorite
8:00 AM – 1:30 PM
CEST
(302) Canadian Pustular Psoriasis Study (CAPPS): Examining disease burden, treatments and healthcare resource utilization for palmoplantar pustulosis in Canada
Favorite
8:00 AM – 1:30 PM
CEST
(303) Estimation of period-based costs associated with individual chronic complications of rare inherited diseases, in the context of multimorbidity, using real-world data.
Favorite
8:00 AM – 1:30 PM
CEST
(304) Healthcare resource utilization among patients with multiple system atrophy in US claims database
Favorite
8:00 AM – 1:30 PM
CEST
(305) High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
Favorite
8:00 AM – 1:30 PM
CEST
(306) Incident Treatment and Adverse Liver Outcomes among Patients with Primary Sclerosing Cholangitis: An Analysis of Real-World Data
Favorite
8:00 AM – 1:30 PM
CEST
(307) Long-term Safety and Effectiveness of Taliglucerase-alfa for Gaucher disease (GD): An International, Prospective 10-Year Follow Up Drug Registry Study (TALIAS)
Favorite
8:00 AM – 1:30 PM
CEST
(308) Prevalence, Comorbidities, and Healthcare Costs of Rare Genetic Diseases in Germany: A Claims Database Study
Favorite
8:00 AM – 1:30 PM
CEST
(309) Race and sex differences in healthcare resource utilization among patients with myasthenia gravis in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(310) Retrospective Chart Review Data Collection to Generate External Comparator Arm Populations: Considerations and Suggestions for Reducing Key Biases
Favorite
8:00 AM – 1:30 PM
CEST
(311) Sickle Cell Disease: Comorbidities, Treatment Patterns, and Healthcare Resource Utilization
Favorite
8:00 AM – 1:30 PM
CEST
(312) Strategy for identifying data sources in a rare disease through data landscaping and maximizing the usefulness of the results for researchers
Favorite
8:00 AM – 1:30 PM
CEST
(313) To be an Orphan Disease or Not to Be: An Evaluation of Prevalence Estimates for Cancers Near the Orphan Status Threshold and Implications for Orphan Drug Planning
Favorite
8:00 AM – 1:30 PM
CEST
(314) Treatment of systemic lupus erythematosus: analysis of treatment patterns in adult and paediatric patients across four European countries
Favorite
8:00 AM – 1:30 PM
CEST
(315) Treatments of multiple myeloma in Europe from 2012 to 2022: a population-based network cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(316) Understanding the Prevalence of Transthyretin Amyloidosis (ATTR) in Europe: A Comprehensive Literature Review
Favorite
8:00 AM – 1:30 PM
CEST
(317) Use of European rare disease registries to describe the natural history and disease progression of Spinal Muscular Atrophy (SMA) over time
Favorite
8:00 AM – 1:30 PM
CEST
(318) Comparative effectiveness and safety of single-inhaler triple therapy for COPD
Favorite
8:00 AM – 1:30 PM
CEST
(319) Continuity of care in primary care for young children with asthma: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(320) Cost-effectiveness of triple therapy compared to dual therapy in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
CEST
(321) DARWIN EU® - Background Rates of Outcomes of Interest in Patients with Severe Asthma
Favorite
8:00 AM – 1:30 PM
CEST
(322) Efficacy and safety of biologics in asthma and chronic rhinosinusitis with nasal polyps: a systematic review
Favorite
8:00 AM – 1:30 PM
CEST
(323) High Systemic Corticosteroid Burden Among Patients with Uncontrolled Moderate-to-severe Asthma in the US
Favorite
8:00 AM – 1:30 PM
CEST
(324) Identification of Individuals with Severe Asthma in United States Claims Data
Favorite
8:00 AM – 1:30 PM
CEST
(325) Impact of elexacaftor/tezacaftor/ivacaftor on hospital healthcare resource utilization in cystic fibrosis: Danish nationwide register study
Favorite
8:00 AM – 1:30 PM
CEST
(326) Sex differences in the risk of exacerbations among patients with chronic obstructive pulmonary disease: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(327) The Fracture Risk of Asthma Patients with Low Bone Mineral Density: Hospital-Based Cohort Study in Taiwan
Favorite
8:00 AM – 1:30 PM
CEST
(328) A Comprehensive Review and Meta-analysis of COVID-19 Vaccine Studies in Vulnerable Populations- Analysis of 126 observational and clinical trials up to November 2022
Favorite
8:00 AM – 1:30 PM
CEST
(329) A Population Database Analysis To Estimate The Varicella Vaccine Effectiveness In Children <14 Years In A High Vaccination Coverage Area From 2004 To 2022
Favorite
8:00 AM – 1:30 PM
CEST
(330) A population-based observational study of determinants of varicella vaccination in the private market in Denmark
Favorite
8:00 AM – 1:30 PM
CEST
(331) Active Safety Monitoring of COVID-19 Vaccines in France using Patient-Reported Outcomes
Favorite
8:00 AM – 1:30 PM
CEST
(332) Background Rates of Neuroinflammatory Disorders and Atrial Fibrillation – Conditions of Interest for Vaccine Safety Studies
Favorite
8:00 AM – 1:30 PM
CEST
(333) Case Series Analysis of Immune-Mediated Neurological Events in Vaccinees following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(334) Characterization of COVID-19 vaccine data in the Sentinel System
Favorite
8:00 AM – 1:30 PM
CEST
(335) Claims Profile Review to Assess Age at Vaccination Among Young Males Who Appeared to Receive the 4-valent Human Papillomavirus (HPV) Vaccine (4vHPV vaccine) in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(336) Comparing disparities in uptake of COVID-19 and influenza vaccination among pregnant women, September 2020 and March 2022: English and Welsh national cohorts
Favorite
8:00 AM – 1:30 PM
CEST
(337) Comparison of Influenza and COVID-19 Vaccine Coverage Rates by Age in Selected Geographies During the 2022-2023 Season
Favorite
8:00 AM – 1:30 PM
CEST
(338) Cumulative Rates of Serious and Adverse Events of Special Interest in Vaccinees Following AZD1222 (ChAdOx1 nCoV-19): Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(339) Data mining for adverse events of influenza vaccine in children using a tree-temporal scan statistic analysis
Favorite
8:00 AM – 1:30 PM
CEST
(340) Differences in self-reported adverse events after the first mRNA COVID-19 vaccination between pregnant and non-pregnant women
Favorite
8:00 AM – 1:30 PM
CEST
(341) Early use of Moderna’s mRNA-1273.815 monovalent vaccine: a descriptive analysis of a US Claims database
Favorite
8:00 AM – 1:30 PM
CEST
(342) Effectiveness of BNT162b2 and CoronaVac in individuals with multimorbidity: a territory-wide case-control study
Favorite
8:00 AM – 1:30 PM
CEST
(343) Effectiveness of Maternal mRNA COVID-19 Vaccination Against COVID-19 Symptomatic Infection and Hospitalization in Infants Aged < 6 Months During the SARS-CoV-2 Omicron-Predominant Period: VENUS Study
Favorite
8:00 AM – 1:30 PM
CEST
(344) Effectiveness Of Pertussis Vaccines In Children Between 2013 And 2019 In France: A Nested Matched Case Control Study Using The National Health Data System
Favorite
8:00 AM – 1:30 PM
CEST
(345) Effectiveness of primary COVID-19 vaccination against severe infection in pediatrics: a cohort study using two linked data sources in Spain.
Favorite
8:00 AM – 1:30 PM
CEST
(346) Immunization Status of Rotavirus Vaccine among Infants in Korea
Favorite
8:00 AM – 1:30 PM
CEST
(347) Interim Utilization Results from a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(348) MotherToBaby Pregnancy Studies, Vaccines in Medications Surveillance System (VAMPSS) COVID-19 Vaccines Study
Favorite
8:00 AM – 1:30 PM
CEST
(349) Observed versus Expected Analysis of Adverse Events of Special Interest after AZD1222 (ChAdOx1 nCoV-19) Vaccination: Results from a UK Post-authorisation Active Surveillance Study
Favorite
8:00 AM – 1:30 PM
CEST
(350) Pilot study on the application of rapid cycle analysis method for post-marketing active vaccine safety surveillance using COVID-19 vaccines in Japan: the VENUS Study
Favorite
8:00 AM – 1:30 PM
CEST
(351) Rates of SARS-CoV-2 Breakthrough Infection or Severe COVID-19 and Associated Risk Factors After Primary and Booster Vaccination Against COVID-19 in the Netherlands
Favorite
8:00 AM – 1:30 PM
CEST
(352) Safety of Ancestral Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years
Favorite
8:00 AM – 1:30 PM
CEST
(353) Serious Neurological Adverse Reactions to SARS-CoV-2 Vaccines in Chile
Favorite
8:00 AM – 1:30 PM
CEST
(354) Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis after COVID-19 Vaccination
Favorite
8:00 AM – 1:30 PM
CEST
(355) Tetanus, Diphtheria, Pertussis (Tdap) Vaccination During Pregnancy and Initiation of Human Milk Feeding
Favorite
8:00 AM – 1:30 PM
CEST
(356) The Persistence in Risk and Effect Of COVID-19 Vaccination on Long-Term Health Consequences One Year After SARS-Cov-2 Infection: A Territory-Wide Cohort Study in Hong Kong
Favorite
8:00 AM – 1:30 PM
CEST
(357) The Use of Background Incidence Rates to Support Vaccine Safety Monitoring: Challenges and Future Opportunities in the Framework of Beyond COVID Monitoring Excellence (BeCOME)
Favorite
8:00 AM – 1:30 PM
CEST
(358) Use of test-negative designs in pharmacoepidemiology: focus on vaccine effectiveness 2013-2023
Favorite
8:00 AM – 1:30 PM
CEST
(359) Vaccination Use among Pregnant Women 2016-2023: An Analysis Using Healthcare Claims
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT01) Medication non-adherence and risk of mortality among patients with incident heart failure: a cohort study using the Clinical Practice Research Datalink (CPRD) Aurum database
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT02) Gender Differences in Statin Persistence across Racial and Ethnic Groups among Persons with HIV in the United States
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT03) Implementation of Clinical Pharmacist’s Services in Patients Receiving Oral Oncolytics and its Effects on Medication Adherence and Quality of Life: A Hospital-Based Prospective Interventional Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT04) Socioeconomic and demographic groups associated with adherence to antidiabetic medications in individuals with type 2 diabetes: A nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT05) Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: 1-year mirror-image study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT06) Comparative Analysis of Treatment Discontinuation Among P2Y12 receptor inhibitors Post-Acute Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials.
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT07) Factors Associated with Adherence to Long-Acting Injectable Antipsychotics Among Medicare Beneficiaries
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT08) The Relationships Between ADHD/ADHD Medication and the Persistence of Anti-Hypertensive Medication?
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT09) Evaluating the Association of Denosumab versus Bisphosphonates on Diabetes Risk: A Nationwide Cohort Study and Meta-Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT10) Effectiveness and Safety of SGLT2 Inhibitor Treatment on Renal Outcomes in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study in South Korea
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT11) Association between N-acetylcysteine and risk of acute cardiovascular events in illicit substance users: nationwide case-case-time-control study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT12) Effectiveness of everolimus on transplant outcomes in Korean liver transplant recipients: a nationwide cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT13) Association between Antipsychotic Therapy and Suicide Risk in Patients with Treatment-Resistant Depression – A clone-censor-weight Approach to Address Immortal Time Bias
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT14) Multinational prescribing trends of lithium from 2001 to 2019: a retrospective observational study using population-based databases from 17 countries and one special administrative region
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT15) Impact of antithrombotics on the association between proton pump inhibitors and ischaemic stroke: standard and modified self-controlled case series
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT16) Association Between Sacubitril/Valsartan and Risk of Dementia in Heart Failure Patients: A Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT17) A post-authorization safety study of golimumab in ulcerative colitis using the Spanish ENEIDA registry (MK8259-042)
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT18) Socioeconomic Conditions Effects On Biological Prescriptions For Inflammatory Bowel Disease In Brazil
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT19) Tree-based mining of real-world data for potential safety signals associated with the use of dupilumab in the United States (2017-2023)
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT20) Adherence Differences Between Self-Administered and Provider-Administered Biologics Among Patients with Rheumatoid Arthritis During the COVID-19 National Emergency
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT21) The Risk of Venous Thromboembolism in Two of the Most Common Inflammatory Skin Diseases - a Comparative Cohort Study Consisting of the Adult Populations of Atopic Dermatitis and Psoriasis in the Swedish Specialist Care
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT22) Biologic Drugs Use In Inflammatory Bowel Diseases: A Systematic Review And Meta-Analysis
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT23) An Active Safety Surveillance Using Real-World Evidence (ASSURE) Approach to Pharmacovigilance Signal Evaluation: The case of infliximab and alternative autoimmune conditions
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT24) Trajectories of adherence to biological drugs in patients with inflammatory bowel diseases: the VALORE project
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT25) Discrete Choice Experiment (DCE) as A Tool to Elicit Patient Preferences in A Complex Benefit-Risk Evaluation: A Rimonabant Case Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT27) A Comparative Analysis of Imposed Post-Authorization Measures for Advanced Therapy Medicinal Products Approved Between 2009-2013 in Europe and in United States of America
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT28) Limited impact of Direct Healthcare Professional Communications when using optimal outcomes and appropriate study populations: a systematic review.
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT29) Assessing use of the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies (RIMES) checklist in risk minimization evaluation studies in the EUPAS register
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT30) Identifying regulatory outcomes of Multi-Database and non- Multi-Database non-interventional Post Authorisation Safety Studies using publicly available information
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT31) Perspectives of People With Type 2 Diabetes Mellitus Towards a Decision Aid Assessing Preferences of Glucose-Lowering Drugs: The Dilemma of Choosing
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT32) Impact of risk communication on thrombosis with thrombocytopenia syndrome for COVID-19 adenovirus vector vaccines on European healthcare professionals
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT33) Incidence, Prevalence, and Survival of Breast Cancer in the United Kingdom from 2000-2021: A Population-Based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT34) Bruton's Tyrosine Kinase-Induced Musculoskeletal Disorders: A Real-World Safety Data Analysis of FAERS Database and Meta-Analysis of Randomized Controlled Trials
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT35) Live birth rate in female breast cancer survivors compared with the general population: matched cohort study using linked UK electronic health records
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT36) Real-world Treatment Pattern and Overall Survival of Stage III and IV Non‑Small‑Cell Lung Cancer Patients: An Analysis using German Cancer Registry Data
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT37) Use of anthracyclines and trastuzumab in breast cancer patients with comorbid cardiovascular disease in Sweden: a cross-sectional study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT38) Do Multimorbidity, Polypharmacy, and Socioeconomic Position Interact to Increase Colorectal Cancer Mortality? A Danish Nationwide, Population-Based Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT39) Trajectories of Antidepressant Use After Tamoxifen Initiation Among Young and Middle Age Women with Breast Cancer
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT40) Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT41) Effectiveness of Axicabtagene Ciloleucel versus Conventional Treatments as First-line Therapy in Patients With High-risk Large B-cell Lymphoma: a Retrospective External Comparator Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT42) Stem Cell Therapy in Avascular Necrosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT43) Risk Management of Authorised Advanced Therapy Medicinal Products in the EU
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT44) Planned and Ongoing EMA-mandated Post-approval Observational Studies of Cell & Gene Therapies (CGT): What Can We Learn from Study Characteristics?
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT45) Post-marketing Safety Assessment of CAR T-cell Therapies: Analysis of Individual Case Safety Reports in the VigiBase
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT46) Comparative Effectiveness of Denosumab versus Bisphosphonates among Treatment-Experienced Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT47) Do Selective Serotonin Reuptake Inhibitors differ in depression treatment outcomes in Older Adults with Chronic Somatic Diseases? Evidence from a Danish Target Trial Emulation Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT48) Comparative Risk of Neurodevelopmental Disorders Between Children Exposed to β-lactam and non-β-lactam Antibiotics During Gestation: An Emulated Target Trial
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT49) Comparative Effectiveness of Denosumab versus Zoledronic Acid among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT50) No Elevated Risk of Cataract in Amiodarone Users: A Population-based Active-Comparator Study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT51) Central vs. Non-central Angiotensin Converting Enzyme-inhibitors and the risk of Alzheimer's disease: A cohort study
Favorite
8:00 AM – 1:30 PM
CEST
(CSPOT53) Comparison of Anemia Outcomes between SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Patients with Chronic Kidney Disease: Multi-institutional Cohort Study with Target Trial Emulation in Taiwan
Favorite
